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ABSTRACT 
 
Background:  
Diabetes mellitus is one of the main threats to human health in the twenty first century 
in Sudan and worldwide. Uncontrolled diabetes mellitus will be complicated by 
dyslipidemia which leads to serious cardiovascular events increasing diabetes 
morbidity and mortality. Coronary heart disease is the number one cause of death 
among diabetics. Despite all these facts, no study assessing coronary heart disease risk 
in diabetics has been conducted in Sudan up to date. 
Design:  
Prospective hospital based cross-sectional study. 
Setting:  
Diabetes outpatient clinic in Soba University Hospital during the period from July to 
December 2009. 
Objectives:  
This study is conducted to determine the lipid profile patterns in adult diabetic 
patients in Soba University Hospital and to calculate the estimated coronary heart 
disease risk using Framingham scoring system. 
Methods:  
This study included 80 adult diabetic patients. Diabetic patients with other causes of 
dyslipidemia were excluded from the study. Eligible patients were consented, data 
were collected by detailed questionnaire and two blood samples were collected from 
each patient. The fasting lipid profile (triglyceride, total cholesterol, LDL-cholesterol 
and HDL-cholesterol), fasting blood glucose and the 2 hours postprandial blood 
glucose were measured by the auto-analyzer COBAS INTEGRA 400 plus (ROCHE). 
Then, for each patient we used some of the lipid profile parameters  (total cholesterol, 
LDL-cholesterol and HDL-cholesterol) together with other Coronary heart disease 
risk predictors like age, smoking, blood pressure values to calculate the Coronary 
heart disease risk in the following  10 years using the Framingham scoring system. 
The data were analyzed using the MATLAB and the SPSS programs. 
Results:  
It was found that 53% of the studied cases had diabetes mellitus chronic 
complications.  Evidence of ischemic cardiac disease was found in 21% of the cases, 
mainly in type 2 patients. Hypertension was found in 29% of the cases. The studied 
cases showed increased body mass index, the mean was 27 kg/m2 which represents 
overweight (SD 3.99). Obesity and overweight were found in 70% of the cases mostly 
occurring in type 2 patients. The short-term glycemic control was poor in 65% of the 
cases. All these markedly contributed to the poorer diabetes mellitus control, the 
dyslipidemia and the higher coronary heart disease risk. The lipid profile testing was 
requested only in 27.5% of the cases, reflecting the decreased awareness about the 
importance of dyslipidemia in diabetics among the medical staff who used to take 
care of them. The lipid profile of the studied cases was interpreted according to the 
National Cholesterol Education Program (NCEP) guidelines. It showed .hypertri-
glyceridemia in 36%, hypercholesterolemia in 31%, decreased HDL-cholesterol to 
levels conferring increased coronary heart disease risk in 95% and increased LDL-
cholesterol in 77% of the studied cases. Both type 1 and 2 diabetics had mean lipid 
profile values showing borderline high LDL, moderate risk HDL, normal triglyceride. 
The mean total cholesterol was borderline high in type 1 and desirable in type 2 
patients. The lipid profile of type 1 patients is worse than that of type 2 in respect to 
the degree & the number of patients having the dyslipidemia. It further worsened 
significantly with prolonged disease duration,(P < 0.05 ). The mean estimated 
coronary heart disease risk in the next 10 years was 14%, which was calculated using 
the Framingham scoring system. This is high in comparison with low risk individuals  
(person the same age, optimal blood pressure, LDL-C 100-129mg/dl or cholesterol 
160-199 mg/dl, HDL-C 45 mg/dl for men or 55 mg/dl for women, non-smoker, no 
diabetes) in whom  the risk was  6%. 
Conclusion:  
According to our knowledge, it is the first time such a study is done in Sudan 
estimating the coronary heart disease risk in diabetics using the Framingham scoring 
system. The studied cases showed dyslipidemia in the form of: decreased HDL-
cholesterol, increased LDL-cholesterol, hypertriglyceridemia and hypercholestero-
lemia (in decreasing order of frequency).The lipid profile in type 1 patients was worse 
than type 2. The estimated coronary heart disease risk in the next 10 years was found 
to be remarkably high in the studied cases. These alarming findings should draw 
attention of health policy makers to increase the awareness about the importance of 
lipid profile testing in diabetics, implement coronary heart disease risk calculation and 
adopt a more efficient multidisciplinary team approach in diabetes management. 
 ﺺــاﻟﻤﺴﺘﺨﻠ
  
  : ﻋﻥ ﻤﻭﻀﻭﻉ ﺍﻟﺒﺤﺙ ﺨﻠﻔﻴﺔ
ﻭﻗﺩ ﺘﻡ ﻭﺼﻔﻪ ﻜﺄﺤﺩ ﻤﻬﺩﺩﺍﺕ ﺼﺤﺔ . ﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ ﻤﺸﻜﻠﺔ ﺼﺤﻴﺔ ﻤﺘﻨﺎﻤﻴﺔ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ ﻭﺍﻟﻌﺎﻟﻡ ﻜﻜل ﻴﻌﺩ
ﺍﻟﺴﻜﺭﻱ ﺍﻟﻐﻴﺭ ﻤﻨﻀﺒﻁ ﻴﺅﺩﻱ ﻟﻤﻀﺎﻋﻔﺎﺕ ﻜﺎﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ ﻭﺍﻟﺘﻲ ﺒﺩﻭﺭﻫﺎ . ﻓﻲ ﺍﻟﻘﺭﻥ ﺍﻟﺤﺎﺩﻱ ﻭﺍﻟﻌﺸﺭﻴﻥ ﻹﻨﺴﺎﻥﺍ
ﻤﺭﺽ . ﺓ ﻭﻨﺴﺒﺔ ﻭﻓﻴﺎﺕ ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱﻴﻤﻜﻥ ﺃﻥ  ﺘﺅﺩﻱ ﻟﺤﺎﻻﺕ ﻤﺭﻀﻴﺔ ﻗﻠﺒﻴﺔ ﺨﻁﻴﺭﺓ ﻤﻤﺎ ﺴﻴﺯﻴﺩ ﻤﻥ ﻤﻌﺎﻨﺎ
ﺒﺎﻟﺭﻏﻡ ﻤﻥ ﻜل ﻫﺫﻩ ﺍﻟﺤﻘﺎﺌﻕ؛  ﻟﻡ ﻴﺘﻡ . ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻨﺩﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻫﻭ ﺍﻟﺴﺒﺏ ﺍﻷﻭل ﻟﻠﻭﻓﺎﺓ ﻋ
ﺇﺠﺭﺍﺀ ﺩﺭﺍﺴﺔ ﺘﻘﻴﻡ ﻤﻌﺩل ﺨﻁﻭﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ ﺤﺘﻰ 
  .ﺍﻵﻥ
   :ﺍﻟﺒﺤﺙ ﺘﺼﻤﻴﻡ
  . ﺎﻟﻤﺴﺘﺸﻔﻰﻁﻌﻴﺔ  ﺒﻤﻘ ﺔﻤﺘﺎﺒﻌ ﺩﺭﺍﺴﺔ
   :ﺍﻟﺒﺤﺙ ﻤﻜﺎﻥ
  .9002ﺍﻟﺴﻜﺭﻱ ﺨﻼل ﺍﻟﻔﺘﺭﺓ ﻤﻥ ﻴﻭﻟﻴﻭ ﺤﺘﻰ ﺩﻴﺴﻤﺒﺭ  ﻟﻤﺭﻀﻰﺍﻟﻌﻴﺎﺩﺓ ﺍﻟﺨﺎﺭﺠﻴﺔ  -ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻲ  ﻤﺴﺘﺸﻔﻰ
   :ﺍﻟﺒﺤﺙ ﻫﺩﻑ
ﺃﻨﻤﺎﻁ ﺍﻟﺩﻫﻭﻥ ﻋﻨﺩ ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﺍﻟﺒﺎﻟﻐﻴﻥ ﺒﻤﺴﺘﺸﻔﻰ ﺴﻭﺒﺎ ﺍﻟﺠﺎﻤﻌﻲ ﻭﻟﺤﺴﺎﺏ  ﺩﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ ﻟﺘﺤﺩﻴ ﺠﺭﺍﺀﺇ ﺘﻡ
 .ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ  ﻓﺭﺍﻤﻨﺠﻬﺎﻡ ﺍﻟﺤﺴﺎﺒﻲ  ﺘﻬﻡﻤﻌﺩل ﺨﻁﻭﺭﺓ ﺇﺼﺎﺒ
    :ﺍﻟﺒﺤﺙ ﻁﺭﻴﻘﺔ
ﺍﻟﺴﻜﺭﻱ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﺴﺒﺏ ﺁﺨﺭ  ﻤﺭﻀﻰﻤﺭﻴﺽ ﺒﺎﻟﻎ ﻤﺼﺎﺏ ﺒﺎﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﺠﻨﺴﻴﻥ  08ﻀﻤﺕ ﺍﻟﺩﺭﺍﺴﺔ 
ﻻﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ ﺘﻡ ﺇﻗﺼﺎﺅﻫﻡ ﻤﻥ ﺍﻟﺩﺭﺍﺴﺔ ، ﺍﻟﻤﺭﻀﻰ ﺍﻟﺫﻴﻥ ﺘﻨﻁﺒﻕ ﻋﻠﻴﻬﻡ ﺸﺭﻭﻁ ﺍﻟﺩﺭﺍﺴﺔ ﺘﻡ ﺃﺨﺫ ﻤﻭﺍﻓﻘﺘﻬﻡ 
ﻗﻤﻨﺎ ﺒﻘﻴﺎﺱ ﺍﻟﺩﻫﻭﻥ .ﻤﻊ ﺍﻟﻤﻌﻠﻭﻤﺎﺕ ﻤﻨﻬﻡ ﻋﻥ ﻁﺭﻴﻕ ﺍﻹﺴﺘﺒﻴﺎﻥ ﺜﻡ ﺘﻡ ﺠﻤﻊ ﻋﻴﻨﺘﻴﻥ ﻤﻥ ﺍﻟﺩﻡ ﻤﻥ ﻜل ﻤﺭﻴﺽﻭﺠ
( ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻤﻨﺨﻔﺽ ﺍﻟﻜﺜﺎﻓﺔ ﻭ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟﻜﺜﺎﻓﺔ. ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﺍﻟﻜﻠﻲ, ﺍﻟﺘﺭﺍﻴﺠﻠﻴﺴﺭﺍﻴﺩ)ﻋﻨﺩ ﺍﻟﺼﻴﺎﻡ 
 SABOC :ﺒﻭﺍﺴﻁﺔ ﺠﻬﺎﺯﻓﻲ ﺤﺎﻟﺔ ﺍﻟﺼﻴﺎﻡ ﻭ ﺒﻌﺩ ﺴﺎﻋﺘﻴﻥ ﻤﻥ ﺘﻨﺎﻭل ﺍﻹﻓﻁﺎﺭ  ﺍﻟﺩﻡﺒﺎﻹﻀﺎﻓﺔ  ﻟﺴﻜﺭ 
ﺒﻌﺩ ﺫﻟﻙ ﻭﻟﻜل ﻤﺭﻴﺽ ﻗﻤﻨﺎ ﺒﺤﺴﺎﺏ ﻤﻌﺩل  ﺜﻡ .  rezylanaotua )EHCOR(sulp 004 ARGETNI
, ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﺍﻟﻜﻠﻲ )  ﺍﻟﻘﻠﺒﻴﺔ  ﺒﺎﺴﺘﺨﺩﺍﻡ ﺒﻌﺽ ﻨﺘﺎﺌﺞ ﻓﺤﺹ ﺍﻟﺩﻫﻭﻥ ﺘﺎﺠﻴﺔﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟ ﺓﺨﻁﻭﺭ
ﻤﺘﻨﺒﺌﺎﺕ ﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻤﻊ ﺒﻌﺽ (  ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻤﻨﺨﻔﺽ ﺍﻟﻜﺜﺎﻓﺔ ﻭ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟﻜﺜﺎﻓﺔ
 .ﻲﻤﺴﺘﺨﺩﻤﻴﻥ ﻨﻅﺎﻡ ﻓﺭﺍﻤﻨﺠﻬﺎﻡ ﺍﻟﺤﺴﺎﺒ, ﻀﻐﻁ ﺍﻟﺩﻡ ﺒﺎﻹﻀﺎﻓﺔ ﻟﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ , ﺍﻟﺘﺩﺨﻴﻥ,  ﺍﻟﺠﻨﺱ, ﺍﻟﻌﻤﺭ: ﻤﺜل 
 .SSPSﻭ  BALTAMﺍﻟﺘﺤﻠﻴل ﺍﻹﺤﺼﺎﺌﻲ ﻟﻠﻨﺘﺎﺌﺞ ﺒﻭﺍﺴﻁﺔ ﺒﺭﺍﻤﺞ  ﺘﻡ
   :ﺍﻟﺒﺤﺙ ﻨﺘﺎﺌﺞ
ﻟﻤﺩﺭﻭﺴﺔ ﺒﻬﺎ ﻤﻀﺎﻋﻔﺎﺕ ﻤﺯﻤﻨﺔ ﻟﻤﺭﺽ ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﺍ% 35ﺃﻥ  ﻭﺠﺩ.ﻤﺭﻴﻀﺎ ﺒﺎﻟﻐﺎ 08ﻫﺫﻩ ﺍﻟﺩﺭﺍﺴﺔ  ﺸﻤﻠﺕ
ﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻘﻠﺏ ﺍﻟﻤﺯﻤﻨﺔ ﺍﻟﻨﺎﺘﺠﺔ ﻋﻥ ﻤﺭﺽ . ﻤﺭﺽﺍﻟﺴﻜﺭﻱ ﻭ ﺍﻟﺘﻲ ﺘﺯﺩﺍﺩ ﺒﺼﻭﺭﺓ ﻤﻠﺤﻭﻅﺔ ﺒﺎﺯﺩﻴﺎﺩ ﻤﺩﺓ ﺍﻟ
ﻤﻥ % 92ﻭﺠﺩ ﺍﺭﺘﻔﺎﻉ ﻀﻐﻁ ﺍﻟﺩﻡ ﻓﻲ .ﻤﻥ ﺍﻟﻤﺭﻀﻲ ﺨﺎﺼﺔ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ% 52.12ﺍﻟﺴﻜﺭﻱ ﻭﺠﺩﺕ ﻓﻲ 
  ﺎﺩﺓﻴﻌﺎﺩل ﺯﻴ ﻭﻫﻭ ﻡ\ﻜﺠﻡ 72ﺠﺴﻡ ﺒﻤﺘﻭﺴﻁ ﻴﺒﻠﻎ ﻜﺘﻠﺔ ﺍﻟ ﺩلﺍﻟﺤﺎﻻﺕ ﺍﻟﻤﺩﺭﻭﺴﺔ ﺯﻴﺎﺩﺓ ﻓﻲ ﻤﻌ ﺃﻅﻬﺭﺕ .ﺍﻟﺤﺎﻻﺕ
ﻓﻲ  ﺔﺨﺎﺼ, ﻤﻥ ﺍﻟﺤﺎﻻﺕ ﺍﻟﻤﺩﺭﻭﺴﺔ% 07ﺍﻟﺴﻤﻨﺔ ﻭ ﺯﻴﺎﺩﺓ ﺍﻟﻭﺯﻥ ﻭﺠﺩﺍ ﻓﻲ (. 99.3ﺍﻹﻨﺤﺭﺍﻑ ﺍﻟﻤﻌﻴﺎﺭﻱ )ﻭﺯﻥ 
 ﻫﺫﻩ. ﻤﻥ ﺍﻟﻤﺭﻀﻰ%56ﺴﻴﺌﺎ ﻟﺩﻯ  ﺎﻥﺘﻨﻅﻴﻡ ﺍﻟﺴﻜﺭﻱ ﻟﻠﻤﺩﻯ ﺍﻟﻘﺼﻴﺭ ﻜ.  ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ
ﺍﻟﺘﺎﺠﻴﺔ  ﺍﻷﻭﻋﻴﺔﺨﻁﻭﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ  ﻻﺯﺩﻴﺎﺩ ﺃﺩﻯﺍﻟﺯﻴﺎﺩﺓ ﻓﻲ ﻤﻌﺩل ﻜﺘﻠﺔ ﺍﻟﺠﺴﻡ ﻭﺴﻭﺀ  ﺘﻨﻅﻴﻡ ﺍﻟﺴﻜﺭﻱ 
ﻨﺘﺎﺌﺞ ﻓﺤﺹ ﺍﻟﺩﻫﻭﻥ ﺘﻡ ﺘﻘﻴﻴﻤﻬﺎ ﺒﺤﺴﺏ ﻤﻭﺠﻬﺎﺕ ﺒﺭﻨﺎﻤﺞ ﺘﻌﻠﻴﻡ ﺍﻟﻜﻭﻟﻴﺴﺘﻴﺭﻭل ﺍﻟﻭﻁﻨﻲ ﻭﻗﺩ ﺃﻅﻬﺭﺕ . ﺍﻟﻘﻠﺒﻴﺔ
ﻨﻘﺼﺎﻥ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻤﻨﺨﻔﺽ , %13ﺯﻴﺎﺩﺓ ﺍﻟﻜﻭﻟﻴﺴﺘﻴﺭﻭل ﻓﻲ  , %   63ﺯﻴﺎﺩﺓ ﺍﻟﺘﺭﺍﻴﺠﻠﻴﺴﻴﺭﺍﻴﺩ ﻓﻲ  :  ﺍﻟﺘﺎﻟﻲ
ﻤﺘﻭﺴﻁ ﻗﻴﺎﺱ ﺍﻟﺩﻫﻭﻥ ﻟﻤﺭﻀﻰ . ﻤﻥ ﺍﻟﺤﺎﻻﺕ % 77ﻓﻲ  ﻜﺜﺎﻓﺔﻭﺯﻴﺎﺩﺓ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟ% 59ﺍﻟﻜﺜﺎﻓﺔ ﻓﻲ 
ﺨﻁﻭﺭﺓ ﻤﺘﻭﺴﻁﺔ ﻟﻠﻜﻭﻟﻴﺴﺘﻴﺭﻭل  ﻤﻨﺨﻔﺽ , ﺤﺩ ﺍﻟﺨﻁﻭﺭﺓ ﻟﻠﻜﻭﻟﻴﺴﺘﻴﺭﻭل ﺍﻟﻜﻠﻲ ﻬﺭﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻋﻴﻥ ﺃﻅ
ﻭل ﺍﻟﻜﻠﻲ ﺒﻠﻎ ﺤﺩ ﺍﻟﺨﻁﻭﺭﺓ ﻟﺩﻯ ﺍﻟﻤﺭﻀﻰ ﻤﻥ ﺍﻟﻨﻭﻉ ﻤﺘﻭﺴﻁ ﺍﻟﻜﻭﻟﻴﺴﺘﻴﺭ. ﺍﻟﻜﺜﺎﻓﺔ ﻭﻤﺘﻭﺴﻁ ﻁﺒﻴﻌﻲ ﻟﻠﺘﺭﺍﻴﺠﻠﻴﺴﻴﺭﺍﻴﺩ
 ﻤﻥﻗﻴﺎﺱ ﺍﻟﺩﻫﻭﻥ ﻟﻠﻤﺭﻀﻲ . ﺍﻟﻤﺘﻭﺴﻁ ﻓﻲ ﺍﻟﻤﺴﺘﻭﻯ ﺍﻟﻤﻁﻠﻭﺏ  ﻟﺩﻯ ﺍﻟﻤﺭﻀﻰ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻜﺎﻥﺍﻷﻭل ﻭ 
ﺍﻟﻨﻭﻉ ﺍﻷﻭل ﻜﺎﻥ ﺃﺴﻭﺀ ﻤﻥ ﻤﺭﻀﻲ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨﻲ ﻤﻥ ﺤﻴﺙ ﺩﺭﺠﺔ ﺍﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ ﻭ ﻋﺩﺩ ﺍﻟﻤﺭﻀﻲ 
ﻭل، ﺍﻟﺘﺭﺍﻴﺠﻴﻠﻴﺴﻴﺭﺍﻴﺩ ﻭ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟﻜﺜﺎﻓﺔ ﻭ ﺍﻨﺨﻔﺎﺽ ﻓﻲ ﺍﻟﺫﻴﻥ ﻟﺩﻴﻬﻡ ﺍﺭﺘﻔﺎﻉ ﻓﻲ ﺍﻟﻜﻭﻟﻴﺴﺘﺭ
 ﻤﻌﺩل .ﻤﻠﺤﻭﻅﺔ ﻤﻊ ﺯﻴﺎﺩﺓ ﻤﺩﺓ ﺍﻟﻤﺭﺽ ﺒﺼﻭﺭﺓﻨﺘﺎﺌﺞ ﻓﺤﺹ ﺍﻟﺩﻫﻭﻥ ﺘﺯﺩﺍﺩ ﺴﻭﺀﺍ . ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻤﻨﺨﻔﺽ ﺍﻟﻜﺜﺎﻓﺔ
ﺨﻼل ﺍﻟﻌﺸﺭﺓ ﺴﻨﻭﺍﺕ ﺍﻟﻘﺎﺩﻤﺎﺕ ﻜﺎﻥ  ﻘﺩﺭﺓﺨﻁﻭﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﺍﻟﻤ
ﻭﻫﻭ ﻤﻌﺩل ﻤﺭﺘﻔﻊ ﻋﻨﺩ ﻤﻘﺎﺭﻨﺘﻪ . ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ  ﻓﺭﺍﻤﻨﺠﻬﺎﻡ ﺍﻟﺤﺴﺎﺒﻲ%  41ﻭﻗﺩ ﺒﻠﻎ ﺍﻟﻤﺘﻭﺴﻁ   ,ﻤﺭﺘﻔﻌﺎ 
ﺍﻟﻜﻭﻟﻴﺴﺘﻴﺭﻭل  , ﻀﻐﻁ ﺩﻤﻪ ﻤﺜﺎﻟﻲ,ﺸﺨﺹ ﻤﻥ ﻨﻔﺱ ﺍﻟﻌﻤﺭ) ﺒﺎﻟﻤﻌﺩل ﻟﺩﻯ ﺍﻷﺸﺨﺎﺹ ﺍﻟﻤﻨﺨﻔﻀﻲ ﺍﻟﺨﻁﻭﺭﺓ 
ﺩﺴل  \ﻤﻠﺠﻡ 55ﺩﺴل ﻟﻠﺭﺠﺎل ﻭ \ﻤﻠﺠﻡ 54ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟﻜﺜﺎﻓﺔ , ﺩﺴل \ﻤﻠﺠﻡ 921-001ﻤﻨﺨﻔﺽ ﺍﻟﻜﺜﺎﻓﺔ 
  %.6ﻭﺍﻟﺫﻴﻥ ﺒﻠﻎ ﻤﻌﺩل ﺍﻟﺨﻁﻭﺭﺓ ﻟﺩﻴﻬﻡ ( ﻏﻴﺭ ﻤﺩﺨﻥ ﻭﻟﻴﺱ ﻤﺼﺎﺏ ﺒﺎﻟﺴﻜﺭﻱ,ﻟﻠﻨﺴﺎﺀ
   :ﺍﻟﺒﺤﺙ ﻤﻠﺨﺹ
ﻫﺫﻩ ﻫﻲ ﺍﻟﻤﺭﺓ ﺍﻷﻭﻟﻰ ﺍﻟﺘﻲ ﺘﺠﺭﻯ ﺒﻬﺎ ﺩﺭﺍﺴﺔ ﺘﻘﻴﻡ ﻤﻌﺩل ﺨﻁﻭﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ  ﻟﻤﻌﺭﻓﺘﻨﺎ ﻁﺒﻘﺎ
ﻤﻀﺎﻋﻔﺎﺕ ﺍﻟﻘﻠﺏ ﺍﻟﻤﺯﻤﻨﺔ ﺍﻟﻨﺎﺘﺠﺔ   .ﺒﻲﺍﻟﻘﻠﺒﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻓﻲ ﺍﻟﺴﻭﺩﺍﻥ ﺒﺎﺴﺘﺨﺩﺍﻡ ﻨﻅﺎﻡ  ﻓﺭﺍﻤﻨﺠﻬﺎﻡ ﺍﻟﺤﺴﺎ
ﺍﻟﺤﺎﻻﺕ ﺍﻟﻤﺩﺭﻭﺴﺔ  ﺃﻅﻬﺭﺕ .ﻋﻥ ﻤﺭﺽ ﺍﻟﺴﻜﺭﻱ ﺘﻨﺘﺸﺭ ﺒﻴﻥ  ﺍﻟﻤﺭﻀﻲ ﻭ ﺘﺯﺩﺍﺩ ﺴﻭﺀﺍ ﻤﻊ ﺯﻴﺎﺩﺓ ﻤﺩﺓ ﺍﻟﻤﺭﺽ
ﺴﻭﺀﺍ ﻓﻲ ﺘﻨﻅﻴﻡ ﺍﻟﺴﻜﺭﻱ ﻟﻠﻤﺩﻯ  ﻭ( ﻭ ﺯﻴﺎﺩﺓ ﻭﺯﻥ ﻤﻨﺔﺴ)ﺯﻴﺎﺩﺓ ﻜﺘﻠﺔ ﺍﻟﺠﺴﻡ ,ﺍﺯﺩﻴﺎﺩ ﻓﻲ ﺍﻨﺘﺸﺎﺭ ﻀﻐﻁ ﺍﻟﺩﻡ ﺍﻟﻤﺭﺘﻔﻊ
 .ﻱ ﻭﺯﻴﺎﺩﺓ ﻤﻌﺩل ﺨﻁﻭﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔﻜل ﺫﻟﻙ ﺴﺎﻫﻡ ﻓﻲ ﺴﻭﺀ ﺘﻨﻅﻴﻡ ﺍﻟﺴﻜﺭ. ﺍﻟﻘﺼﻴﺭ
ﺍﻟﺤﺎﻻﺕ  ﺃﻅﻬﺭﺕ .ﺒﺄﻫﻤﻴﺔ ﺍﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ  ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻭﺠﺩ ﻤﻨﺨﻔﻀﺎ  ﻋﻨﺩ ﺍﻟﻔﺭﻴﻕ ﺍﻟﻁﺒﻲ ﺍﻟﻭﻋﻲ
, ﺯﻴﺎﺩﺓ ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻋﺎﻟﻲ ﺍﻟﻜﺜﺎﻓﺔ, ﺍﻟﻜﻭﻟﻴﺴﺘﺭﻭل ﻤﻨﺨﻔﺽ ﺍﻟﻜﺜﺎﻓﺔ  ﻨﻘﺼﺎﻥ: ﻴﻠﻲ ﻜﻤﺎﺍﻟﻤﺩﺭﻭﺴﺔ ﺍﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ 
ﺍﺨﺘﻼل ﺍﻟﺩﻫﻭﻥ  ﻟﺩﻯ ﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻷﻭل . ﺠﻠﻴﺴﻴﺭﺍﻴﺩ ﻭ ﺯﻴﺎﺩﺓ ﺍﻟﻜﻭﻟﻴﺴﺘﻴﺭﻭل ﺍﻟﻜﻠﻲﺍﻟﺘﺭﺍﻴ ﺯﻴﺎﺩﺓ
ﻨﻅﺎﻡ   ﺒﺎﺴﺘﺨﺩﺍﻡ .ﻭﻗﺩ ﺍﺯﺩﺍﺩ ﺴﻭﺀﺍ ﺒﻁﻭل ﻤﺩﺓ ﺍﻟﻤﺭﺽ. ﻲﺍﻟﺴﻜﺭﻱ ﻤﻥ ﺍﻟﻨﻭﻉ ﺍﻟﺜﺎﻨ ﺭﻀﻲﻜﺎﻥ ﺃﺴﻭﺀ ﻤﻥ ﻤ
ل ﺍﻟﻌﺸﺭﺓ ﺍﻹﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﺍﻟﻘﻠﺒﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﺨﻼ ﺓﻓﺭﺍﻤﻨﺠﻬﺎﻡ ﺍﻟﺤﺴﺎﺒﻲ ﻭﺠﺩ ﻤﻌﺩل ﺨﻁﻭﺭ
ﺍﻟﻤﺤﺫﺭﺓ ﻴﺠﺏ ﺃﻥ ﺘﺠﺫﺏ ﺍﻨﺘﺒﺎﻩ ﺼﻨﺎﻉ ﺍﻟﻘﺭﺍﺭﺍﺕ  ﺘﺎﺌﺞﺍﻟﻨ ﻫﺫﻩ. ﺴﻨﻭﺍﺕ ﺍﻟﻘﺎﺩﻤﺎﺕ ﻤﺭﺘﻔﻌﺎ ﻟﻠﺤﺎﻻﺕ ﺍﻟﻤﺩﺭﻭﺴﺔ
ﺯﻴﺎﺩﺓ ﺍﻟﻭﻋﻲ ﺒﺄﻫﻤﻴﺔ ﻓﺤﺹ ﺍﻟﺩﻫﻭﻥ , .ﺍﻟﺼﺤﻴﺔ ﻟﻠﻘﻴﺎﻡ ﺒﺈﻨﺸﺎﺀ ﺒﺭﺍﻤﺞ ﺘﻌﻠﻴﻤﻴﺔ ﺃﻜﺜﺭ ﻓﻌﺎﻟﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ
ﺼﺎﺒﺔ ﺒﻤﺭﺽ ﺍﻷﻭﻋﻴﺔ ﺍﻟﺘﺎﺠﻴﺔ ﻟﻤﺭﻀﻰ ﺍﻟﺴﻜﺭﻱ ﻋﻨﺩ ﺍﻟﻤﺭﻀﻰ ﻭ ﺍﻷﻁﺒﺎﺀ ﻭ ﺘﻁﺒﻴﻕ ﺤﺴﺎﺏ ﻤﻌﺩل ﺨﻁﻭﺭﺓ ﺍﻹ
  .ﺍﻟﻘﻠﺒﻴﺔ ﻤﻊ ﺘﺒﻨﻲ ﺒﺭﺍﻤﺞ ﻤﺘﻌﺩﺩﺓ ﺍﻷﻨﻅﻤﺔ ﺃﻜﺜﺭ ﻓﻌﺎﻟﻴﺔ ﻟﻺﻫﺘﻤﺎﻡ ﺒﻜﺎﻓﺔ ﺍﻟﺠﻭﺍﻨﺏ ﺍﻟﺼﺤﻴﺔ ﻟﻌﻼﺝ ﺍﻟﻤﺭﻀﻰ
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1. INTRODUCTION 
 
1.1.1 Global burden of DM: 
Diabetes is a serious, common, costly, but controllable disease. An estimated 30 million 
people worldwide had diabetes in 1985. By 1995 this number has shot up to 135 million 
with prevalence around 4 %. The WHO estimate for the number of people with diabetes 
worldwide in 2000 is 177 million. This will increase to at least 300 million by the year 
2025, with prevalence around 5.4%. The majority of this increase will be in the 
developing countries. These statistics have led to diabetes being described as "one of the 
main threats to human health in the twenty first century"(1,2).  
Diabetes is the sixth leading cause of death in the United States(3). In 1987 in US. the 
prevalence of diagnosed diabetes was 6.8 million. In 2001 the US. Centers for Disease 
Control and Prevention (CDC) estimated a prevalence of 7.9% in adults or 16.7 million 
people. Because at least 30% of all prevalent cases are undiagnosed, it was thought that 
the total number may have been almost 22 million(4). 
There is racial predilection, and by the age of 65, 33% of Hispanics, 25% of blacks, and 
17% of whites in the United States will have diabetes mellitus. In 2002 diabetes mellitus 
was estimated to be responsible for $132 billion in healthcare expenditures in the United 
States. The direct costs were $92 billion, with 50% of that incurred by those older than 
65 years. Approximately one in five American healthcare dollars spent in 2002 was for 
people with diabetes mellitus(4). 
 An estimated 186,000 deaths annually are attributable to diabetes with American 
women twice as likely to die from diabetes mellitus as from breast cancer (4). 
 Diabetes is the number one cause of lower limb amputation not related to trauma, the 
number one cause of acquired blindness and the number one cause of kidney disease 
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leading to dialysis in the United States. Diabetes is a major contributor to cardiovascular 
disease, the number one cause of death in the states. About 65% of people with diabetes 
die from cardiovascular disease(3). 
Diabetes prevalence is rapidly increasing. If current trends continue, 1 in 3 Americans 
will develop diabetes sometime in his or her lifetime, and those with diabetes will lose, 
on average, 10 to 15 years of life(5). 
In the Arab world ,due to urbanization and socioeconomic development ,the people has 
changed their traditional life style and are faced with high prevalence of chronic non-
communicable diseases. In the Omani national survey,1999 ,the prevalence was 
reported to be 10% in  the age category above 20 years (6). Prevalence of DM has been 
estimated to be 9.3% in the total Egyptian population aged above 20 years in a study 
conducted 1995 (7 ). 
In Africa, 80% of people with DM remain undiagnosed. In 2000 there were 7.5 million 
cases of DM in the continent. By 2030 this figure is expected to rise to around 18.2 
million (8). DM is associated with severe morbidity and high mortality rates in Africa 
(9). Death among diabetic Africans is commonly due to acute complications  of DM and 
its treatment. Poverty, malnutrition, erratic supplies of drugs, poor patient education and 
concomitant diseases are major contributory factors to the poor prognosis of DM in the 
continent (10,11). 
1.1.2 Epidemiology of DM in Sudan: 
The prevalence and incidence rates of DM in Sudan, as many other low-income 
countries, are increasing to epidemic proportions, leading to the emergence of a public 
health problem with a major socioeconomic impact(12). A population based survey was 
conducted in the northern state of Sudan in 1992, the prevalence rate of DM and IGT 
were 3.4% and 2.9% respectively in population aging 25 years and above.  The highest 
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prevalence of DM was in the northern state (5.5%), the prevalence in the central state 
was 4% and the lowest prevalence was in the western desert-like Kordofan state 1% (12). 
The prevalence was particularly high (8.3%) in the Danagla tribe in the northern state. A 
subgroup of this community, with Egyptian descent, had a 10.8% prevalence of DM (13). 
The natural history of DM in our population is associated with poor glycemic control, a 
high prevalence of complications and a low quality of life(14). In previous studies type 2 
DM was found to be more common, with severe clinical course and high prevalence of 
acute and chronic complications(15). In type 2 diabetic patients, the prevalence of 
hypertension was 44% compared to non-diabetic subjects(16). The prevalence of 
microvascular and macrovascular complications is high. Retinopathy has approximated 
43%, nephropathy 22%, neuropathy 37%, peripheral vascular disease 10% and 
cerebrovascular accidents 5.5%. The overall prevalence of long term complications was 
67%. Patients with these complications were significantly older, had longer disease 
duration and higher serum cholesterol and triglyceride concentration. The glycemic 
control was adequate in only 12.5% of patients (17). 
The number of patients with DM is increasing. Statistical records showed that the 
number of inpatients was more than doubled (from 5592 to 11262) in 5 years time 
(1999-2003), half of them being in Khartoum state. DM was one of the most common 
10 causes of hospital admission in the years 1998, 2000, 2002. It was also one of the 
most common 10 causes of death in the country in the years 1998, 1999, 2002. In 2004, 
DM was the 9th cause of outpatient visits accounting for 2.7% of all outpatient visits and 
2.6% of all hospital admissions in Khartoum state(18, 19). 
The poor metabolic control of Sudanese diabetic patients was attributed to several 
factors. Decreased diabetes awareness and non-compliance on the part of the patients, 
unavailability and unaffordability of drugs and treatment follow up materials ,reduced 
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levels of well organized diabetes care and poor health service utilization were all 
significant contributing factors. Diabetes education has been mostly offered by doctors 
in a busy clinic atmosphere. We are lacking very essential needs for the proper  
implementation of diabetes care, for example the concept of diabetes educator and the 
educational materials ,national diabetes patient education programs, the availability of 
insulin and other anti diabetic drugs and patients aids like vision aids, therapeutic shoes, 
mobility aids and prosthesis(20). Although considerable improvement has been achieved 
by introduction of specialized multidisciplinary diabetes clinics like Jabir Abo Aliz 
center and other smaller centers, the situation is far beyond covering our population real 
need.  
1.1.3 Diabetic dyslipidemia and cardiovascular disease: 
More cardiovascular disease occurs in patients with either type 1 or 2 diabetes. Among 
the metabolic abnormalities that commonly accompany diabetes are disturbances in the 
production and clearance of plasma lipoproteins. Moreover, development of 
dyslipidemia may be a harbinger of future diabetes. A characteristic pattern, termed 
diabetic dyslipidemia, consists of low high density lipoprotein (HDL), increased 
triglycerides and postprandial lipemia. This pattern is most frequently seen in type 2 
diabetes and may be a treatable risk factor for subsequent cardiovascular disease (21). 
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1.2 LITERATURE REVIEW 
 
1.2.1 Definition and description of diabetes mellitus: 
Diabetes mellitus is a group of metabolic diseases characterized by hyperglycemia 
resulting from defects in insulin secretion, insulin action, or both. The chronic 
hyperglycemia of diabetes is associated with long-term damage, dysfunction, and failure 
of various organs, especially the eyes, kidneys, nerves, heart, and blood vessels (22).  
Several pathogenic processes are involved in the development of diabetes. These range 
from autoimmune destruction of the β-cells of the pancreas with consequent insulin 
deficiency to abnormalities that result in resistance to insulin action. The basis of the 
abnormalities in carbohydrate, fat and protein metabolism in diabetes is deficient action 
of insulin on target tissues. Deficient insulin action results from inadequate insulin 
secretion and/or diminished tissue responses to insulin at one or more points in the 
complex pathways of hormone action. Impairment of insulin secretion and defects in 
insulin action frequently coexist in the same patient, and it is often unclear which 
abnormality, if either alone, is the primary cause of the hyperglycemia  (22). 
Symptoms of marked hyperglycemia include polyuria, polydipsia, weight loss, 
sometimes with polyphagia and blurred vision. Impairment of growth and susceptibility 
to certain infections may also accompany chronic hyperglycemia .(22) 
1.2.2 Types of Diabetes Mellitus: 
1.2.2.1 Type 1 Diabetes Mellitus: 
Type 1 diabetes mellitus was formerly known as IDDM, type I, or juvenile-onset 
diabetes. Approximately 5% to 10% of all individuals with diabetes mellitus are in this 
category. Symptoms (e.g., polyuria, polydipsia and rapid weight loss) usually present 
acutely; individuals have insulinopenia (a deficiency of insulin) because of loss of 
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pancreatic islet beta-cells and depend on insulin treatment to sustain life and prevent 
ketosis(4). Most individuals have antibodies that identify an autoimmune process 
destroying the β-cells. One and usually more of these autoantibodies are present in 85–
90% of individuals when fasting hyperglycemia is initially detected. Also, the disease 
has strong HLA associations, with linkage to the DQA,DQB andDRB genes (22). 
Autoimmune destruction of β-cells has multiple genetic predispositions and is also 
related to environmental factors that are still poorly defined. Although patients are 
rarely obese when they present with this type of diabetes, the presence of obesity is not 
incompatible with the diagnosis. These patients are also prone to other autoimmune 
disorders  (22).  
Some patients, particularly children and adolescents, may present with ketoacidosis as 
the first manifestation of the disease. Others have modest fasting hyperglycemia that 
can rapidly change to severe hyperglycemia and/or ketoacidosis in the presence of 
infection or other stresses. At the latter stage of the disease, there is little or no insulin 
secretion, as manifested by low or undetectable levels of plasma C-peptide. Immune-
mediated diabetes commonly occurs in childhood and adolescence, but it can occur at 
any age, even in the 8th and 9th decades of life (22).   
A minority of patients have a form of type 1 diabetes with no known etiology, no 
evidence of autoimmunity, not HLA associated but  is strongly inherited so called type 
1 idiopathic(22).The peak incidence of this form is in childhood and adolescence(4).  
Individuals with this form of diabetes suffer from episodic ketoacidosis and exhibit 
varying degrees of insulin deficiency between episodes. An absolute requirement for 
insulin replacement therapy in affected patients may come and go(22). 
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1.2.2.2 Type 2 Diabetes Mellitus: 
Formerly known as non-insulin-dependent diabetes NIDDM, type II diabetes, or adult-
onset diabetes, constitutes approximately 90% of all cases of diabetes. Patients (1) have 
minimal symptoms, (2) are not prone to ketosis and (3) are not dependent on insulin to 
prevent ketonuria. Insulin concentrations may be within the reference interval, 
decreased, or increased and most people with this form of diabetes have impaired 
insulin action(4).  
Most patients with this form of diabetes are obese. It is known that obesity promotes 
insulin resistance through the inappropriate activation of gluconeogenesis, through the 
newly discovered condition known as ER (endoplasmic reticulum) stress, which is 
induced by a high fat diet and is overly activated in obese people (23). Patients who are 
not obese by traditional weight criteria may have an increased percentage of body fat 
distributed predominantly in the abdominal region(22).Weight loss alone usually 
improves the hyperglycemia. However, many individuals with type 2 diabetes may 
require dietary manipulation, an oral hypoglycemic agent, or insulin therapy to control 
hyperglycemia(4). 
Most patients acquire the disease after age 40, but it may occur in younger people. Type 
2 diabetes in children and adolescents is an emerging, significant problem(4). The risk of 
developing this form of diabetes increases with age, obesity, and lack of physical 
activity. It occurs more frequently in women with prior GDM and in individuals with 
hypertension or dyslipidemia. The frequency of type 2 DM varies in different 
racial/ethnic subgroups. Autoimmune destruction of β-cells does not occur. It is often 
associated with a strong genetic predisposition, more so than is the autoimmune form of 
type 1 diabetes. However, the genetics of this form of diabetes are complex and not 
clearly defined. Type 2 DM shows a strong familial incidence. The concordance rate in 
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monozygotic (identical) twins is more than 90% and the risk of an individual 
developing DM is greater than 50% if both parents have the condition(24).   
1.2.2.3 Gestational Diabetes Mellitus: 
Gestational Diabetes Mellitus (GDM) is carbohydrate intolerance of variable severity 
with onset or first recognition during pregnancy. Note that women with diabetes who 
become pregnant are not included in this category. Estimates of the frequency of 
abnormal glucose tolerance during pregnancy range from 1% to 14%, depending on the 
population studied and the diagnostic tests employed(4). Deterioration of glucose 
tolerance occurs normally during pregnancy, particularly in the 3rd trimester(22). Women 
with GDM are at a significantly increased risk of subsequent diabetes, predominantly 
type 2. The cumulative incidence of type 2 diabetes after GDM varies among 
populations, ranging from -40% to 70%. At 6 to 12 weeks postpartum, all patients who 
had GDM should be evaluated for diabetes and, if diabetes is not present, be reevaluated 
for diabetes at least every 3 years(4). 
 Although usually asymptomatic and not life threatening to the mother, GDM is 
associated with an increased incidence of neonatal mortality and morbidity, including 
hypocalcemia, hypoglycemia and macrosomia. Maternal complications include a high 
rate of cesarean delivery, hypertension and increased risk of diabetes. Recognition is 
important because therapy can reduce the perinatal morbidity and mortality (4).  
 Risk assessment for GDM should be undertaken at the first prenatal visit.The first step 
in laboratory testing is identical to that for diagnosing diabetes in a non pregnant 
individual (i.e., FPG >126 mg/dl [7 mmol/l] or casual plasma glucose > 200 mg/dl 
[11.1mmol/l] . However, in the absence of that degree of hyperglycemia, average- and 
high-risk patients receive a glucose challenge test following methods based on an 
OGTT. GDM is diagnosed when any two of the following four values are met or 
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exceeded; fasting > 105 mg/dl(5.8 mmol/l);1 hr >190 mg/dl(10.6 mmol/l);2hrs ≥ 165 
mg/dl (9.2mmol/l);or 3 hrs ≥ 145 mg/dl(8.1 mmol/l) (25,26,27). 
1.2.2.4 Other Specific Types of Diabetes Mellitus (secondary diabetes):  
This subclass includes patients in whom hyperglycemia is due to a specific underlying 
disorder, such as (1) genetic defects of beta-cell function (eg.Maturity Onset Diabetes of 
the Young MODY); (2) genetic defects in insulin action; (3) disease of the exocrine 
pancreas: pancreatitis, trauma, infection, pancreatectomy, pancreatic carcinoma, 
extensive cystic fibrosis and hemochromatosis; (4) endocrinopathies (e.g., Cushing 
disease, acromegaly, pheochromocytoma and glucagonoma); (5) the administration of 
hormones or drugs known to induce beta-cell dysfunction (e.g., dilantin and 
pentamidine) or impair insulin action (e.g., glucocorticoids, thiazides, and beta-
adrenergics); (6) infections; (7) uncommon forms of immune-mediated diabetes; or (8) 
other genetic conditions (e.g., Down syndrome, Klinefelter syndrome and 
porphyria)(4,22). 
1.2.3 Impaired Glucose Tolerance: 
Impaired glucose tolerance (IGT) is diagnosed in people who have fasting blood 
glucose concentrations less than those required for diagnosing diabetes mellitus [FPG < 
126 mg/dl(7 mmol/l)], but have a plasma glucose response during the OGTT between 
normal and diabetic states [ 2-hrs postload glucose 140–199 mg/dl (7.8–11.1 mmol/l) ]. 
An OGTT is required to assign a patient to this class. Development of overt diabetes 
occurs at a rate of 1% to 5% per year in people with IGT, but a large proportion 
spontaneously revert to normal glucose tolerance. Microvascular disease is quite rare in 
this group and patients usually do not experience the renal or retinal complications of 
diabetes. Patients have an increased prevalence of atherosclerosis and mortality from 
cardiovascular disease(4). 
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1.2.4 Impaired Fasting Glucose: 
Impaired fasting glucose (IFG) is diagnosed by a fasting glucose value above normal 
but below the concentration for diagnosis of diabetes [FPG 100–125 mg/dl (5.6–6.9 
mmol/l)]. It is a metabolic stage between normal glucose homeostasis and diabetes. As 
with IGT, persons with IFG are at increased risk for the development of diabetes and 
cardiovascular disease. IFG and IGT are not clinical entities, but rather risk factors for 
diabetes and cardiovascular disease(4). 
IFG and IGT are associated with the metabolic syndrome. The National Cholesterol 
Education Program (NCEP) definition of the metabolic syndrome involves 5 risk 
factors, and only 3 out of the 5 are needed to make the diagnosis. Risk factors include 
abdominal obesity, which is a waist circumference greater than 40 inches (102cm) in 
males or 35 inches (88cm) in females; triglycerides of 150 mg/dl or greater; high-
density lipoprotein cholesterol (HDL-C) in men of less than 40 mg/dl (women less than 
50 mg/dl); blood pressure greater than or equal to 130/85 mmHg and fasting glucose of 
100 mg/dl or greater(37) (28).  It is worth mentioning that medical nutrition therapy aimed 
at producing 5–10% loss of body weight, exercise, and certain pharmacological agents 
have been variably demonstrated to prevent or delay the development of diabetes in 
people with IGT; the potential impact of such interventions to reduce cardiovascular 
risk has not been examined to date (22). 
Many individuals with IGT are euglycemic in their daily lives. Individuals with IFG or 
IGT may have normal or near normal glycated hemoglobin levels. Individuals with IGT 
often manifest hyperglycemia only when challenged with the oral glucose load used in 
the standardized OGTT (22). 
1.2.5 Diagnostic criteria for diabetes mellitus:   
1. FPG ≥126 mg/dl (7.0 mmol/l). Fasting is defined as no caloric intake for 10-12 hours. 
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         OR 
2. Symptoms of hyperglycemia and a casual plasma glucose ≥200 mg/dl (11.1 mmol/l). 
Casual is defined as any time of day without regard to time since last meal. The 
classic symptoms of hyperglycemia include polyuria, polydipsia and unexplained 
weight loss.  
          OR 
3. 2-hour plasma glucose ≥200 mg/dl (11.1 mmol/l) during an OGTT. The test should 
be performed as described by the World Health Organization, using a glucose load 
containing the equivalent of 75 g anhydrous glucose dissolved in water. 
In the absence of unequivocal hyperglycemia, these criteria should be confirmed by 
repeat testing on a different day (22,29). 
Screening of high-risk individuals for diabetes is now recommended. The ADA 
considers either FPG or 2-hour OGTT to be appropriate. Testing should be considered 
in all asymptomatic people at age 45 or younger  in subjects at increased risk which 
include : Overweight adult [ Body Mass Index ≥25 kg/m2 (≥23 if Asian American or 
≥26 if Pacific Islander) ]with one or more of the following: Family history with a first-
degree relative with diabetes or Race/Ethnicity like African American, Hispanic/Latino, 
American Indian and Alaska Native, Asian American or Pacific Islander or History of 
gestational diabetes or gave birth to a baby weighing > 9 lbs (4.1kg) or Hypertension 
with blood pressure >140/90  or Abnormal lipid levels with HDL cholesterol level 
<35mg/dl; triglyceride level >250 mg/dl or  IGT or IFG on previous testing or Signs of 
insulin resistance such as acanthosis nigricans or polycystic ovarian syndrome or 
History of vascular disease diagnosed by physical exam and testing or Inactive lifestyle 
being physically active less than three times a week.  
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In the absence of the above risk factors, people age 45 and older are considered at risk 
and should be tested. 
Consider repeat testing at least every three years (30). 
1.2.6 Long-Term Monitoring  (Glycosylated hemoglobins GHb): 
GHb (reflected by Hb A1C) has been firmly established as an index of long-term 
glycemic control over the last 60-120 days (the average life span of circulating red 
blood cells) and as a measure of the risk for the development of complications in 
patients with diabetes mellitus. It has been also used by quality assurance programs to 
assess the quality of diabetes care (4). 
HbA1C is the nonenzymatic glycated product of the hemoglobin beta-chain at the valine 
terminal residue. The number 1C following HbA represents the order in which this 
hemoglobin is detected on chromatography. The A1C constitutes about 60-80% of total 
glycated hemoglobin. It is normally present, albeit at low levels, in circulating red cells 
because of the glycosylation reaction between hemoglobin and circulating glucose. In 
the presence of excess plasma glucose, the hemoglobin beta-chain becomes increasingly 
glycosylated, making the A1C a useful index of glycemic control. Because A1C is 
based on hemoglobin, both qualitative and quantitative variations in hemoglobin can 
affect the A1C value(31). 
The Diabetes Control and Complications Trial (DCCT) documented that there is a direct 
relationship between glycemic control (assessed by Hb A1C) and the risk of developing 
long-term diabetes-related complications. The absolute risks of retinopathy and 
nephropathy were directly proportional to the mean Hb AlC (32). 
The United Kingdom Prospective Diabetes Study (UKPDS) proved that each 1% 
reduction in Hb AlC (e.g., from 8% to 7%) was associated with risk reductions of 37% 
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for microvascular disease, 21% for deaths related to diabetes and 14% for myocardial 
infarction" (33). 
Based on the DCCT and UKPDS, the ADA recommends that a primary treatment goal 
in adults with diabetes should be "near-normal" glycemia with Hb A1C less than 7%. 
Hb AlC, is not recommended for the diagnosis or screening of diabetes at present, but 
may be implemented in the future(32, 33). 
1.2.7 Complications of DM: 
Diabetic ketoacidosis (DKA); which can be the presenting feature of type 1and the 
hyperglycemic hyperosmolar state (HHS) occurring in type 2 DM appear as 2 extremes 
in the spectrum of diabetic decompensation(34). They remain the most serious and life-
threatening acute metabolic complications of diabetes mellitus and are still associated 
with excess mortality. Insulin deficiency is the main underlying abnormality. Associated 
with elevated levels of counter-regulatory hormones, insulin deficiency can trigger 
hepatic glucose production and reduced glucose uptake, resulting in hyperglycemia, and 
can also stimulate lipolysis and ketogenesis, resulting in ketoacidosis. Both 
hyperglycemia and hyperketonemia will induce osmotic diuresis, which leads to 
dehydration(35). Clinical diagnosis is based on the finding of dehydration along with 
high capillary glucose levels with or without ketones in the urine or plasma. The 
diagnosis is confirmed by the blood pH, serum bicarbonate level and serum osmolality. 
Treatment consists of adequate correction of the dehydration, hyperglycemia, 
ketoacidosis and electrolyte deficits. Any comorbid precipitating event (e.g. infection, 
stress, acute illness, trauma or myocardial infarction) should be identified and treated 
appropriately . Both DKA and HHS are medical emergencies and patients with these 
conditions must be admitted to hospital (36).  
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Long-term complications of diabetes can be microvascular which include retinopathy 
with potential loss of vision; nephropathy leading to renal failure; peripheral neuropathy 
with risk of foot ulcers, amputations and Charcot joints; and autonomic neuropathy 
causing gastrointestinal, genitourinary, sexual dysfunction and cardiovascular 
symptoms. Patients with diabetes have an increased incidence of macrovascular 
atherosclerotic cardiovascular, peripheral arterial and cerebrovascular disease. 
Hypertension and abnormalities of lipoprotein metabolism are often found in people 
with diabetes. Diabetes constitutes one of the common causes of secondary 
dyslipidemia(22).  
Complications of diabetes, such as retinopathy, proteinuria and neuromuscular disease, 
are present in approximately 30% of patients at clinical diagnosis of type 2 diabetes. 
The onset of type 2 diabetes probably occurs at least 4 to 7 years before clinical 
diagnosis(4).   
1.2.8 Dyslipidemia in diabetes:  
Hyperlipidemias can be either primary (genetic) or secondary (acquired).The secondary 
causes are much more common, and, since resolution of lipid abnormality should follow 
successful treatment of underlying conditions, management should be directed towards 
the cause. Common causes of secondary dyslipidemia include: obesity, excessive 
alcohol intake, hypothyroidism, nephrotic syndrome, chronic renal failure, cholestasis, 
drugs and diabetes mellitus(22,24). 
Defects in insulin action and hyperglycemia could lead to changes in plasma 
lipoproteins in patients with diabetes. Several factors are likely to be responsible for 
diabetic dyslipidemia: insulin effects on liver apoprotein production, regulation of 
lipoprotein lipase, actions of cholesteryl ester transfer protein and peripheral actions of 
insulin on adipose tissue and muscle (21). 
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In those with type 1 diabetes, plasma lipid and lipoprotein concentrations may be 
normal, but there may be oxidation and glycation of the lipoproteins, which may impair 
their function and/or enhance their atherogenicity(36). In poorly controlled type 1 diabetes 
and ketoacidosis hypertriglyceridemia and reduced HDL commonly occur. Replacement of 
insulin in these patients may correct these abnormalities (21). Type 2 diabetics have less 
dyslipidemia than type 1 patients. The most common lipid profile pattern in type 2 diabetes 
consists of hypertriglyceridemia (hyper-TG), low high-density lipoprotein cholesterol 
(HDL-C) and normal plasma concentrations of low-density lipoprotein cholesterol 
(LDL-C). However, in the presence of even mild hyper-TG, LDL-C particles are 
typically small and dense and may be more susceptible to oxidation. Chronic 
hyperglycemia promotes the glycation of LDL-C and both these processes are believed 
to increase the atherogenicity of LDL-C (37). In contrast to type 1 diabetes, this 
phenotype is not usually fully corrected with glycemic control(21). The atherogenicity of 
the glycated LDL-C is increased by decreasing its affinity to LDL- receptors and 
enhancing its uptake by macrophages (21). 
1.2.8.1 Assessment of the lipid profile in DM: 
 The patient lipaemic state is determined by performing blood lipid profile test after an 
overnight fast of 9-12 hours. Then, the results are interpreted and used to assess the 
CHD risk according to the guidelines of the National Cholesterol Education Program 
(NCEP)- Adult Treatment Panel (ATP ) III as follows(38): 
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• Table 1-1 : LDL Cholesterol*  
Blood level CHD risk 
 <100 mg/dl  Optimal 
 100-129 mg/dl  Near Optimal/Above Optimal 
 130-159 mg/dl  Borderline High 
 160-189 mg/dl  High 
 190 mg/dl  Very high 
*Primary Target of Therapy 
 
• Table 1-2 : Total Cholesterol 
Blood level CHD risk 
 <200 mg/dl  Desirable 
 200-239 mg/dl  Borderline High 
 240 mg/dl  High 
 
• Table 1-3 : HDL Cholesterol 
Blood level CHD risk 
 <40 mg/dl  High 
 40-60 mg/dl  Moderate 
 60 mg/dl  Negative   
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• Table 1-4 : Triglyceride 
Blood level CHD risk 
 < 150 mg/dl  Normal 
  150-199 mg/dl   Borderline high 
  200-499 mg/dl   High 
 500 mg/dl  Very high 
 
1.2.9 Diabetes mellitus and hypertension: 
Hypertension (defined as a blood pressure ≥140/90 mmHg) is an extremely common co-
morbid condition in diabetes, affecting ∼20–60% of patients with diabetes, depending 
on obesity, ethnicity and age. Hypertension substantially increases the risk of both 
macrovascular and microvascular complications, including stroke, coronary artery 
disease, peripheral vascular disease, retinopathy, nephropathy and possibly 
neuropathy(28). 
 Diabetic nephropathy is an important factor involved in the development of 
hypertension in diabetics, particularly type I patients. However, the etiology of 
hypertension in the majority of diabetic patients cannot be explained by underlying renal 
disease and remains "essential" in nature. The goal of antihypertensive therapy in the 
patient with coexistent diabetes is to reduce the cardiovascular risk as well as lowering 
blood pressure (39).  
1.2.10 Cardiovascular disease risk assessment in diabetes: 
Diabetes in adults is associated with a high risk of vascular disease (2- to 4-fold greater 
than that of individuals without diabetes), with Cardio Vascular Disease (CVD)  being 
the primary cause of death among people with type 1 or type 2 diabetes (5,33). Aggressive 
management of all CVD risk factors, including dyslipidemia, is therefore generally 
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necessary(37).Numerous studies have established that when the total cholesterol and 
LDL cholesterol concentrations are high, the incidence and prevalence of coronary heart 
disease CHD are also high. Increased HDL cholesterol concentrations are protective for 
CHD in both epidemiological and clinical trial studies (4).  
Patients with diabetes should be assessed to determine their short- and long-term risks 
for CVD (28).In the Finnish East West Study, patients with diabetes without known heart 
disease had a ~20% chance of having a cardiac event over a 7-year time period (26). 
Clinical assessment can identify those with diabetes whose risk level might be 
considered lower. This includes people meeting all the following criteria: younger 
patients with recent onset of diabetes and without other risk factors for vascular disease 
(e.g. the metabolic syndrome, family history of premature CVD, hypertension, 
smoking) and without other complications of diabetes (including CVD). All patients 
with diabetes have an extremely high lifetime risk of CVD; thus, even if the short term 
risk is lower, early intervention to improve the lipid profile may be warranted. Finally, 
the short- and long-term clinical outcome of patients with diabetes who experience an 
ischemic cardiac event is worse than for those who do not have diabetes. This justifies 
an aggressive CVD risk-factor reduction approach in people with diabetes, unless they 
meet all of the low-risk criteria outlined above (39). 
The major and independent risk factors for CHD are cigarette smoking of any amount, 
elevated blood pressure, elevated serum total cholesterol and low-density lipoprotein 
cholesterol (LDL-C), low serum high-density lipoprotein cholesterol (HDL-C), diabetes 
mellitus and advancing age(40). Preventive efforts should target each major risk factor. 
Any major risk factor, if left untreated for many years, has the potential to produce 
cardiovascular disease (CVD). Nonetheless, an assessment of total (global) risk based 
on the summation of all major risk factors can be clinically useful for 3 purposes: (1) 
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identification of high-risk patients who deserve immediate attention and intervention, 
(2) motivation of patients to adhere to risk-reduction therapies, and (3) modification of 
intensity of risk-reduction efforts based on the total risk estimate. For the latter purpose, 
patients at high risk because of multiple risk factors may require intensive modification 
of 1 risk factors  to maximize risk reduction (38). 
Guidelines for the management of individual risk factors are provided by the second 
Adult Treatment Panel report (ATP II) of the National Cholesterol Education Program 
(NCEP)(38), the sixth report of the Joint National Committee  of the National High Blood 
Pressure Education Program(41) and the American Diabetes Association (ADA)(42). All 
of these guidelines are currently endorsed or supported by the American Heart 
Association (AHA)(38,41,42). 
1.2.10.1 UKPDS risk engine:  
Several software programs are available that assess vascular risk in people with 
diabetes. For example; The United Kingdom Prospective Diabetes Study (UKPDS) risk 
engine. The UKPDS Risk Engine is a type 2 diabetes specific risk calculator based on 
53,000 patients years of data from the UK Prospective Diabetes Study, which also 
provides an approximate 'margin of error' for each estimate. The UKPDS Risk Engine 
provides risk estimates and 95% confidence intervals, in individuals with type 2 
diabetes not known to have heart disease, for: 
- non-fatal and fatal coronary heart disease. 
- fatal coronary heart disease. 
- non-fatal and fatal stroke. 
- fatal stroke. 
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These can be calculated for any given duration of type 2 diabetes based on current age, 
sex, ethnicity, smoking status, presence or absence of atrial fibrillation and levels of 
HbA1c, systolic blood pressure, total cholesterol and HDL cholesterol (43). 
 
 
1.2.10.2 ADA Risk Calculator: 
ADA Launches Diabetes Risk Calculator.It is a Web-based Diabetes Personal Health 
Decisions (Diabetes PHD).The patient or the clinician can use the free online program. 
After entering personal health information such as age, sex, weight, family medical 
history, medications, blood lipid values and retinal problems, the user will receive a 
profile detailing his or her risks of diabetes and its complications. The report also 
provides an accurate picture of how the individual can alter those risks with actions such 
as losing weight, quitting smoking, reducing blood pressure or cholesterol levels(42). 
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1.2.10.3 Framingham Heart Study Prediction Score Sheets: 
The Framingham Heart Study is a project of the national Heart, Lung and Blood 
institute and Boston University. 
The CHD predictors are: Sex, Age, Diabetes, Smoking, blood pressure categories, 
NCEP total cholesterol categories or LDL cholesterol categories and HDL cholesterol 
categories 
The quantitative relationship between these predictors and CHD risk has been elucidated 
by the Framingham Heart Study(40) and other studies. These studies show that the major 
risk factors are additive in predictive power. Accordingly, the total risk of a person can 
be estimated by summing of the risk imparted by each of the major risk factors. The 
update of the 1991 Framingham coronary prediction algorithm provides estimates of 
total CHD risk (risk of developing one of the following: angina pectoris, myocardial 
infarction or coronary disease death) over the course of 10 years. Separate score sheets 
are used for men and women and the factors used to estimate risk include age, blood 
cholesterol (or LDL cholesterol), HDL cholesterol, blood pressure, cigarette smoking 
and diabetes mellitus (see tables below). Relative risk for CHD is estimated by 
comparison to low risk Framingham participants(40). 
Framingham scores estimate risk for persons without clinical manifestations of CHD 
and it does not assess risk for other cardiovascular outcomes(40). Therefore, the scores 
apply only to primary prevention, i.e. prevention in persons without established CHD. 
Once coronary atherosclerotic disease becomes clinically manifest, the risk for future 
coronary events is much higher than that for patients without CHD (38), regardless of 
other risk factors, and in this case, Framingham scoring no longer applies. The AHA and 
ACC have issued joint guidelines for the management of risk factors for patients with 
established CHD and other forms of atherosclerotic disease(44). 
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Steps for estimating CHD risk in men using the Framingham scoring : 
Step 1 
Age 
Years LDL Pts Chol Pts
 30-34  -1  [-1] 
 35-39  0  [0] 
 40-44  1  [1] 
 45-49  2  [2] 
 50-54  3  [3] 
 55-59  4  [4] 
 60-64  5  [5] 
 65-69  6  [6] 
 70-74  7  [7] 
 
 Step 2 
LDL-C 
 (mg/dl)  (mmol/l)  LDL Pts 
 <100  <2.59   -3 
 100-129  2.60-3.36   0 
 130-159  3.37-4.14   0 
 160-190  4.15-4.92   1 
 ≥190   ≥4.92   2 
  
Cholesterol 
(mg/dl)  (mmol/l)  Chol Pts 
 <160  <4.14  [-3] 
 160-199  4.15-5.17  [0] 
 200-239  5.18-6.21  [1] 
 240-279  6.22-7.24  [2] 
 ≥280  ≥7.25  [3] 
 
 Step 3 
HDL-C 
(mg/dl) (mmol/l) LDL Pts Chol Pts 
<35 <0.90 2 [2] 
35-44 0.91-1.16 1 [1] 
45-49 1.17-1.29 0 [0] 
 50-59  1.30-1.55  0  [0] 
 ≥60  ≥1.56  -1  [-2] 
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 Step 4 
Blood Pressure 
Systolic 
(mm Hg) 
Diastolic (mm Hg) 
<80 80-84 85-89 90-99 ≥100 
<120 0 [0]pts     
120-129  0 [0]pts    
130-139   1 [1]pts   
140-159    2 [2]pts  
≥160     3 [3]pts 
*Note: When systolic and diastolic pressures provide different estimates for point 
scores, use the higher number. 
 
Step 5 
Diabetes 
 LDL Pts Chol Pts 
No 0 [0] 
Yes 2 [2] 
 
Step 6 
Smoker 
 LDL Pts Chol Pts 
No 0 [0] 
Yes   2   [2] 
 
Step 7 (sum from Steps 1-6) 
Adding up the points 
  Age ------------------- 
  LDL-C or Chol ------------------- 
  HDL-C ------------------- 
  Blood Pressure ------------------- 
  Diabetes ------------------- 
  Smoker ------------------- 
  Point total ------------------- 
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Step 8 (determine CHD risk from point total) 
CHD Risk 
LDL Pts 
Total 
10 Yr 
CHD Risk 
Chol Pts 
Total 
10 Yr 
CHD Risk 
<-3 1%   
-2 2%   
-1 2% [<-1] [2%] 
0 3% [0] [3%] 
1 4% [1] [3%] 
2 4% [2] [4%] 
3 6% [3] [5%] 
4 7% [4] [7%] 
5 9% [5] [8%] 
6 11% [6] [10%] 
7 14% [7] [13%] 
8 18% [8] [16%] 
9 22% [9] [20%] 
10 27% [10] [25%] 
11 33% [11] [31%] 
12 40% [12] [37%] 
13 47% [13] [45%] 
≥14 ≥56% [≥14] [≥53%] 
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Step 9 (compare to average person your age) 
Comparative Risk 
Age 
(years) 
Average 
10 Yr CHD Risk 
Average 
10 Yr Hard* CHD Risk
Low** 
10 Yr CHD Risk 
30-34 3% 1% 2% 
35-39 5% 4% 3% 
40-44 7% 4% 4% 
45-49 11% 8% 4% 
50-54 14% 10% 6% 
55-59 16% 13% 7% 
60-64 21% 20% 9% 
65-69 25% 22% 11% 
70-74 30% 25% 14% 
 
*Hard CHD events exclude angina pectoris 
**Low risk was calculated for a person the same age, optimal blood pressure, LDL-C 
100-129mg/dl or cholesterol 160-199 mg/dl, HDL-C 45 mg/dl for men or 55 mg/dl for 
women, non-smoker, no diabetes. 
Users of this risk algorithm should be aware of several caveats: 
• The risk estimating score sheets are only for persons without known heart disease.  
• The Framingham Heart Study risk algorithm encompasses only coronary heart 
disease, not other heart and vascular diseases.  
• The Framingham Heart Study population is almost all Caucasian. The Framingham 
risk algorithm may not fit other populations quite as well.  
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• For some of the sex-age groups in Framingham, the numbers of events are quite small. 
Therefore, the estimates of risk for those groups may lack precision.  
• The Framingham risk score estimates the risk of developing CHD within a 10-year 
time period. This risk score may not adequately reflect the long-term or lifetime CHD 
risk of young adults, which is: one in two for men and one in three for women.  
• The presence of any CHD risk factor requires appropriate attention because a single 
risk factor may confer a high risk for CHD in the long run, even if the 10-year risk 
does not appear to be high.  
• Since age is a prominent determinant of the CHD risk score, the 10-year hazards of 
CHD are, on average, high in older persons. This may over-identify candidates for 
aggressive interventions. Relative risk estimates (risk in comparison with low risk 
individuals) may be more useful than absolute risk estimates in the elderly.  
•  The score derived from this algorithm should not be used in place of a medical 
examination(40).  
1.2.11 Management of diabetes:  
People with diabetes can take action to lower their risk for heart attack, stroke and other 
diabetes complications by following an individualized meal plan, engaging in regular 
physical activity, avoiding tobacco use and taking medicines as prescribed and most 
importantly controlling blood glucose, blood pressure, and blood lipids.(45,46)  also called 
the ABCs of diabetes which stand for: (47) 
A is for A1C, previously known as hemoglobin A1C. The goal for most people with 
diabetes is (1) A1C  <7. An A1C of 7 corresponds to an average blood glucose level of 
150 mg/dL. (2) Preprandial plasma glucose 90–130 mg/dl (3) Peak postprandial plasma 
glucose < 180 mg/dl (usually 1 to 2 hours after the start of a meal) 
B is for blood pressure. The goal for most people with diabetes is <130/80 mm Hg. 
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C is for cholesterol. The goal for people with diabetes is an LDL level of <100 mg/dl, 
an HDL level of >40 mg/dl in men and >50in women, and triglycerides level of 
<150(47). 
1.2.11.1 Blood glucose management: 
Many people with type 2 diabetes can control their blood glucose by following a healthy 
meal plan and exercise program, losing excess weight and taking oral hypoglycemic  
medications. Some people with type 2 diabetes may also need insulin to control their 
blood glucose. To survive, people with type 1 diabetes must have insulin delivered by 
injection or a pump(45). Many people with diabetes also need to take medications to 
control their cholesterol and blood pressure(45). 
A multidisciplinary team approach; with providers of foot, dental, and eye care beside 
the others;  is critical to success in diabetes care and complications prevention. Medical 
nutrition therapy education by a dietitian is critical to developing an individualized meal 
plan(46). Diabetes educators help people with or at risk for diabetes gain the knowledge 
and problem-solving and coping skills needed to successfully self-manage the disease 
and its related conditions(45). 
 Lipid and blood pressure management:  
Dyslipidemia and hypertension commonly coexist with type 2 diabetes and are clear 
risk factors for cardiovascular disease; and diabetes itself confers independent risk. 
Extensive trial evidence shows the efficacy of lipid-lowering therapy and targeted 
treatment of hypertension to prevent or slow cardiovascular disease onset in people with 
diabetes. Lipid and blood pressure levels should be treated more aggressively in patients 
with diabetes than in the general population(48),because of the increased risk of 
cardiovascular and kidney diseases. Taken together, improved management of glucose, 
blood pressure and LDL-cholesterol, along with abstinence from smoking, can lead to 
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major reductions in the risk of both small and large vessel complications associated with 
diabetes(48). 
1.2.11.2 Lipid management: 
To reduce the risk of cardiovascular disease, blood lipids need regular measurement and 
effective management; especially high LDL cholesterol, high total cholesterol and low 
HDL cholesterol. Statins are the initial medications of choice for most people with 
elevated LDL cholesterol. Lifestyle modification, weight loss and increased physical 
activity should be recommended(48). 
Statin therapy should be added to lifestyle therapy, regardless of baseline lipid levels, 
for diabetic patients with overt CVD and those without CVD who are over the age of 40 
and have one or more other CVD risk factors. For lower-risk patients without overt 
CVD and under the age of 40, statin therapy should be considered in addition to lifestyle 
therapy if LDL cholesterol remains >100 mg/dl or in those patients with multiple CVD 
risk factors.  
In individuals without overt CVD, the primary goal is an LDL cholesterol <100 mg/dl. 
In individuals with overt CVD, a lower LDL cholesterol goal of <70 mg/dl, using a high 
dose statin, is an option(48). 
1.2.11.3 Blood pressure management: 
Clinical trials have demonstrated clear benefits of hypertension control on both macro- 
and micro-vascular complications of diabetes. Control of hypertension is essential in 
order to reduce cardiovascular, kidney and eye disease risk(48).  
Strategies to reduce sodium intake and excess body weight, avoiding excessive alcohol 
consumption, and increasing activity levels, may have antihypertensive effects similar 
to pharmacologic monotherapy. This can be applied for individuals with diabetes and 
mild hypertension (systolic blood pressure 130–139 mmHg or diastolic blood pressure 
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80–89 mmHg). If the blood pressure is ≥140 mmHg systolic and/or ≥90 mmHg diastolic 
at the time of diagnosis, pharmacologic therapy should be added or initiated. Multidrug 
therapy usually is required to achieve and maintain a blood pressure goal of <130/80 
mmHg that is recommended for most people with diabetes. At every visit to the health 
care team, blood pressure should be measured and treatment adjusted if necessary(48). 
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1.3 JUSTIFICATION 
 
• Diabetes mellitus is a growing health problem in Sudan and world wide. 
• Dyslipidemia is a well known complication of uncontrolled diabetes mellitus. 
Unrecognized or maltreated dyslipidemias can result in serious cardiovascular 
events which significantly increase diabetes morbidity and mortality. 
• Assessment of CHD risk in diabetes patients has never been practiced in Sudan 
despite its proven importance and influence in the diabetes management. 
• Putting in mind these facts this study is designed to explore the lipid profile 
patterns occurring in adult Sudanese diabetic patients & to use the results 
together with other predictors to assess the CHD risk using the Framingham 
scoring system. 
• Knowing the type of dyslipidemia and the estimated CHD risk will help both the 
diabetics as well as their treating physicians by providing treatment goals to 
identify and reduce the factors associated with the development and progression 
of CHD in diabetics. 
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1.4 OBJECTIVES 
 
1.4.1 General objectives: 
To identify the lipid profile patterns in adult Sudanese diabetic patients and to use these 
findings to calculate the estimated CHD risk. 
 
1.4.2 Specific objectives: 
• To estimate the prevalence of hypertension in adult Sudanese diabetic patients. 
• To calculate the BMI of the studied cases, to identify the prevalence of obesity 
and overweight in adult Sudanese diabetic patients and to relate it to the type of 
DM. 
• To determine the short-term diabetes control by measuring FBG and 2hr PP 
blood glucose in adult Sudanese diabetic patients. 
• To measure the fasting lipid profile (cholesterol, triglyceride, HDL-cholesterol 
and LDL-cholesterol), identify the associated dyslipidemias & relate them to the 
type of DM in adult Sudanese diabetic patients. 
• To estimate the 10 years CHD risk in adult Sudanese diabetic patients by using 
the patient sex, age, blood pressure, smoking status and lipid profile as indicated 
by the Framingham scoring system. 
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2. MATERIALS AND METHODS  
 
2.1 MATERIALS 
2.1.1 Study design: 
The study is a hospital-based cross-sectional study. 
2.1.2 Study area: 
The study was conducted in Soba university Hospital at the diabetes out-patient clinic. 
The clinic was established on 8/4/2008 and now it is attended by over 600 patients. The 
medical staff is headed by endocrinology consultant and consists of 4 medical officers, 
2 sisters, a medical nutritionist and a laboratory technologist. The clinic is held twice 
per week.  
The collected samples were analyzed at the chemical pathology unit in SUH.  
2.1.3 Study duration:  
The study was conducted during the period from July to December 2009. 
2.1.4 Study population:  
Adult Sudanese males and females with type 1or type 2 diabetes mellitus attending the 
diabetes out-patient clinic at Soba university hospital. 
2.1.5 Inclusion criteria: 
Diabetic males and females older than 20 years of age who voluntarily accepted to 
participate in this study and are not having any of the exclusion criteria. 
2.1.6 Exclusion criteria: 
Diabetic patients who have any of the following: 
• unwilling to participate      
• taking lipid lowering drugs  
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• Having other causes of dyslipidemia; e.g. thyroid  disorders, chronic renal 
failure, nephrotic syndrome, cholestasis, excessive alcohol intake and drugs like 
beta-blockers . 
2.1.7 Data collection: 
Data were collected from patients by filling a pre-designed interview questionnaire 
which includes personal data, diabetes type, duration of diabetes and its management, 
diagnosed diabetes clinical complication, smoking, alcohol consumption, hypertension 
and blood pressure values, the BMI (weight in Kg/height in m2) , the  results of their 
investigations (FBG,2hrPP  and lipid profile) and the estimated 10 years CHD risk is 
then calculated (using the Framingham scoring). 
2.1.8  Sample size: 
The study has included 80 diabetic patients and 20 age and sex matched healthy 
controls. 
2.1.9 Ethical consideration: 
All the participating patients were informed about the significance of lipid profile 
testing and the CHD risk assessment, the results of their investigations were sent to the 
treating physicians to help in the patients' management. 
2.1.10 Specimen collection: 
The patients came to the diabetic clinic in the morning (8-9 am) after 10-12 hours 
overnight fast. At that time 5 ml of venous blood were withdrawn by standard procedure 
from the fasting patients and then divided into 2 containers, 2.5ml into lithium heparin 
container to estimate fasting lipid profile and 2.5ml into fluoride oxalate container to 
estimate fasting plasma glucose level. After that the patients had their usual breakfast 
and came back after 2 hours another 2.5ml of blood were withdrawn into fluoride 
oxalate container to estimate the 2 hours postprandial blood glucose. 
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2.2 Methodology: 
The specimens were analyzed using COBAS INTEGRA 400 plus (Roche) 
2.2.1 Triglyceride 
2.2.1.1 Test principle: 
Enzymatic –colorimetric method (GPO/PAP) with glycerol phosphate oxidase and 4-
aminophenazone. 
Triglycerides are hydrolyzed by lipoprotein lipase (LPL) to glycerol and fatty acids. 
Glycerol is then phosphorylated to glycerol-3-phosphate by ATP in a reaction catalyzed 
by glycerol kinase (GK). The oxidation of glycerol-3-phosphate is catalyzed by glycerol 
phosphate oxidase(GPO) to form dihydroacetone phosphate and hydrogen 
peroxide(H2O2). In the presence of peroxidase(POD), hydrogen peroxide affects the 
oxidative coupling of 4-chlorophenol and 4-aminophenazone to form a red colored 
quinoneimine dye, which is measured at 512 nm. The increase in absorbance is directly 
proportional to the concentration of triglycerides in the sample. 
Triglycerides ⎯⎯ →⎯LPL  glycerol + fatty acids 
Glycerol+ ATP ⎯⎯ →⎯GK  glycerol-3-phosphate + ADP 
Glycerol-3-phosphate + O2 ⎯⎯ →⎯GPO  dihydroacetone phosphate + H2O2. 
 2H2O2 + 4-aminophenazone ⎯⎯ →⎯POD  quinoneimine dye + 4-chlorophenol+4H2O 
2.2.2 Cholesterol  
2.2.2.1 Test principle: 
 Enzymatic –colorimetric method (CHOD/PAP) with cholesterol esterase, cholesterol 
oxidase, and 4-aminoantipyrine.  
Cholesterol esterase (CE) hydrolyzes cholesterol esters to form free cholesterol and free 
fatty acids. Cholesterol oxidase (CHOD) then catalyzes the oxidation of cholesterol to 
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form cholest-4-ene-3-one and H2O2. In the presence of peroxidase (POD), the hydrogen 
peroxide  
formed affects the oxidative coupling of phenol and 4-amino-antipyrine(4-AAP) to form 
a red colored quinoneimine dye. The color intensity of the red quinoneimine dye formed 
is directly proportional to the cholesterol concentration. It is determined by measuring 
the increase in absorbance at 520 nm. 
Cholesterol esters + H2O ⎯→⎯CE  cholesterol + fatty acids 
Cholesterol + O2 ⎯⎯⎯ →⎯CHOD  cholest-4-ene-3-one + H2O2 
2H2O2 + 4-AAP+ phenol ⎯⎯ →⎯POD  quinoneimine dye +4 H2O 
2.2.3 HDL-Cholesterol: 
2.2.3.1 Test principle: 
Homogeneous enzymatic colorimetric assay. 
In the presence of magnesium sulfate and dextran sulfate, water-soluble complexes with 
LDL, VLDL, and chylomicrons are formed which are resistant to Poly Ethylene Glycol 
(PEG)-modified enzymes. The cholesterol concentration of HDL-cholesterol is 
determined enzymatically by cholesterol esterase and cholesterol oxidase coupled with 
PEG to the amino groups (approximately 40%). Cholesterol esters are broken down 
quantitatively into free cholesterol and fatty acids by cholesterol esterase. In the 
presence of oxygen, cholesterol is oxidized by cholesterol oxidase to 4-cholestenone 
and hydrogen peroxide. The color intensity of the blue quinoneimine dye formed is 
directly proportional to the HDL-cholesterol concentration. It is determined by 
measuring the increase in absorbance at 583 nm. 
HDL-cholesterol esters + H2O ⎯⎯⎯⎯⎯⎯⎯⎯⎯ →⎯ esterase lcholestero-PEG  HDL-cholesterol + RCOOH 
HDL-cholesterol + O2 ⎯⎯⎯⎯⎯⎯⎯⎯⎯ →⎯ oxidase lcholestero-PEG 4-cholestenone+ H2O2 
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2 H2O2 + 4-aminoantipyrine + HSDA+ H ⎯⎯⎯⎯ →⎯peroxidase  purple blue pigment + 4 H2O 
2.2.4 LDL-Cholesterol: 
2.2.4.1 Test principle: 
Homogeneous enzymatic colorimetric assay. 
This automated method for the direct determination of LDL-cholesterol takes advantage 
of the selective micellary solubilization of LDL-cholesterol by a nonionic detergent and 
the interaction of a sugar compound and lipoproteins (VLDL and chylomicrons) . When 
a detergent is included in the enzymatic method for cholesterol determination 
(cholesterol esterase and cholesterol oxidase coupling reaction), the relative reactivities 
of cholesterol in the lipoprotein fractions increase in this order: HDL < chylomicrons < 
VLDL < LDL. In the presence of Mg++, a sugar compound markedly reduces the 
enzymatic reaction of the cholesterol measurement in VLDL and chylomicrons. The 
combination of a sugar compound with detergent enables the selective determination of 
LDL-cholesterol in the serum. In the presence of oxygen, cholesterol is oxidized by 
cholesterol oxidase to 4-cholestenone and hydrogen peroxide. The color intensity of the 
blue quinoneimine dye formed is directly proportional to the LDL-cholesterol 
concentration. It is determined by measuring the increase in absorbance at 583 nm. 
LDL-cholesterol ester + H2O ⎯⎯⎯⎯⎯⎯⎯⎯⎯⎯ →⎯ esterase lcholesterodetergent  cholesterol + free fatty 
acid (selective micellary solubilization) 
LDL-cholesterol + O2 ⎯⎯⎯⎯⎯⎯⎯ →⎯ oxidase lcholestero 4-cholestenone+ H2O2 
2 H2O2 + 4-aminoantipyrine + HSDA+ H+H2O2 ⎯⎯⎯⎯ →⎯peroxidase  purple blue pigment +5 
H2O 
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2.2.5 Glucose  
2.2.5.1 Test principle: 
Enzymatic –colorimetric reference method with hexokinase . Hexokinase (HK) 
catalyzes the phosohorylation of glucose by ATP to form glucose-6-phosphate and 
ADP. To follow the reaction, a second enzyme glucose-6-phosphate dehydrogenase 
(G6PDH) is used to catalyze the oxidation of glucose-6- phosphate by NAD+ to form 
NADH. The concentration of NADH formed is directly proportional to the glucose 
concentration. It is determined by measuring the increase in absorbance at 340 nm.
  
D-Glucose + ATP ⎯⎯ →⎯HK D-glucose-6-phosphate+ ADP 
D-glucose-6-phosphate +NAD+ ⎯⎯⎯ →⎯G6PDH D-6-phosphogluconate +NADH+ 
H+  
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3. RESULTS 
 
3.1. Age and sex distribution of the studied cases: 
Eighty patients were included in this study, mean age 52.3 years, SD 11.708, SEM 
1.309 
Males 23(29%) and females 57(71%) as shown in (Figures 1, 2) 
3.2. Type of DM: 
The majority of patients belong to type 2 DM which included 75 patients(93.75%); 
where only 5 patients belong to type 1 DM (6.25%)  as shown in (Figure 3). 
3.3. Duration of DM in the studied cases: 
DM duration less than 1 year (18.75%), from 1-10 years (47.5%), more than 10 years 
(33.75%), see (Figure 4) 
3.4. Type of diabetes management: 
Diet only 3 patients (3.75%), oral hypoglycemic tablets 55 patients (68.75%), insulin 16 
patients (20%), insulin and oral hypoglycemic tablets 6 patients (7.50%) as shown in 
(Figure 5).  
3.5. Family history of DM: 
Present in 44 patients (55%) and absent in 36 patients (45%), as shown in (Figure 6). 
3.6. Smoking and alcohol consumption in the studied cases: 
Smokers were 7 (8.75%) and non-smokers 73(91.25%), see (Figure 7). 
Alcoholics were 4 (5%) and non-alcohol consumers were 76 (95%), see (Figure 8). 
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3.7. Diabetes mellitus related complications in the studied cases: 
Eye complications were present in 22 patients (27.5%), renal complications in 5 patients 
(6.25%), cardiac complications in 17 patients (21.25%), peripheral neuropathy in 23 
patients (28.75%), whereas 38 patients (47.5%) have no complication, see (Figure 9). 
3.8. Relation between disease duration and development of diabetes 
related complications: 
Prolonged diabetes duration is associated with increased rate of development of DM 
related complications as shown in (Tables 1, 2, 3, 4 and 5). 
3.9. Prevalence of hypertension in the studied cases: 
Known hypertensive patients were 23 (28.75%) and the non-hypertensive were 57 
patients (71.25%), see (Figure 10). 
3.10. Body Mass Index of the studied cases: 
Using The WHO categories of the BMI: underweight (BMI <20 kg/m2), healthy (BMI 
20-24.9 kg/m2), overweight (BMI 25-29.9 kg/m2), obese (BMI 30-39.9 kg/m2), very 
obese (BMI > 40 kg/m2).  
In the studied cases, 3.75 % were underweight, 26.25% had healthy BMI, 50% were 
overweight, 20% were obese and none of the cases is in the very obese category.   
The mean 26.7 kg/m2 (overweight), SD 3.99, SEM 0.446. See (Figure 11). 
3.11. Glycemic control in the studied cases: 
Fasting blood glucose:  
Categories: desirable (< 126mg/dl) - high (>126mg/dl).  
Patients: desirable in 33% and high in 67%. See (Figure 12). 
2 hours post-prandial blood glucose:  
Categories: desirable (< 200mg/dl) - high (>200mg/dl). 
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Patients: desirable in 38% and high in 62%. See (Figure 13). 
3.12. Previous lipid profile testing: 
Requested in 22 patients (27.50%) and absent in 58 patients (72.50%). See (Figure 14). 
3.13. Lipid profile in the studied cases: 
Classified into categories according to the guidelines of the National Cholesterol 
Education Program (NCEP) Adult Treatment Panel III (ATPIII) (40). 
Cholesterol: 
NCEP Categories: desirable (< 200mg/dl), borderline high (200-239 mg/dl), high 
(≥240mg/dl)  
Patients: desirable 55 patients (68.75%), borderline high 15 patients (18.75%), high 10 
patients (12.5%). See (Figure 15). 
Hypercholesterolemia is present in 31% of the cases, mean cholesterol 189.8 mg/dl 
(desirable according to the NCEP). 
Triglyceride:  
NCEP Categories: normal (< 150mg/dl), borderline high (150-199mg/dl), high (200-
499mg/dl), very high ≥ 500 mg/dl. 
 Patients: normal 63.75%, borderline high 20%, high 16.25%. See (Figure 16). 
Hypertriglyceridemia is found in 36.25% of the cases, mean TG 142.5 mg/dl (normal 
according to the NCEP) 
High density lipoprotein (HDL): in terms of CHD risk 
NCEP Categories: Major risk (< 40mg/dl), moderate risk (40-59mg/dl), no risk (≥ 
60mg/dl) 
 Patients: Major risk 51.25%, moderate risk 43.75%, no risk 5%. See (Figure 17). 
Decreased HDL to a level causing increased CHD risk is found in 95% of the cases, 
mean HDL 41.1 mg/dl(moderate risk according to the NCEP) 
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Low density lipoprotein (LDL): in terms of CHD risk 
NCEP Categories: Optimal risk (< 100mg/dl), above optimal risk (100-129mg/dl), 
borderline high risk (130-159mg/dl), high risk (160-189mg/dl), very high risk 
(≥190mg/dl)   
Patients: Optimal risk 23.75%, above optimal risk 28.75%, borderline high risk 26.75%, 
high risk 8.75%, very high risk 12.5%. See (Figure 18). 
Increased LDL with resultant increase in CHD risk is found in 76% of the cases, mean 
LDL     134.4 mg/dl(borderline high risk according to the NCEP) 
3.14. Lipid profile Vs type of DM: 
In type 1 DM patients the mean values for the lipid profile are: cholesterol 209 mg/dl, 
TG 143mg/dl, HDL 42mg/dl, LDL 138mg/dl. (borderline high cholesterol, normal TG, 
moderate risk HDL and borderline high LDL) 
In type 2 DM patients the mean values for the lipid profile are: cholesterol 189mg/dl, 
TG 142 mg/dl, HDL 41mg/dl, LDL 134 mg/dl. (desirable cholesterol, normal TG, 
moderate risk HDL and borderline high LDL)  
Lipid profile in type 1 DM patients is worse than that of type 2 patients. 
3.15. Relation between disease duration and lipid profile: 
Prolonged disease duration is significantly associated with worsening of the lipid 
profile, in the form of increased triglycerides, increased total cholesterol, increased LDL 
and decreased HDL.  
3.16. Estimating coronary heart disease (CHD) risk: 
Using Framingham heart study prediction score which estimates the patient risk of 
developing CHD in the next 10 years. 
Using LDL score the mean 14.53, SD 9.951, SEM 1.244. See (Figure 19). 
Using total cholesterol score the mean 13.06, SD 9.057, SEM 1.132. See (Figure 20). 
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Figure 1: Age distribution of the study population 
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Figure 2: Sex distribution of the study population 
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Figure 3: Type of diabetes in the study population   
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Figure 4: Duration of diabetes in the study population 
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Figure 5: Type of diabetes management  in the study population 
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Figure 6: Family history of diabetes  in the study population 
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Figure 7: Smoking in the study population 
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Figure 8: Alcohol consumption in the study population 
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Figure 9: DM complications in the studied cases Vs type of DM 
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Table 1:  DM duration Vs complication 
Duration (in years) Complications Total 
Yes 
No.           % 
No 
No.           % 
< 1    12     (80%) 3      (20%) 15 
1-10   19      (50%) 19     (50%) 38 
> 10   6      (22%) 21    (78%) 27 
Total   37        43 80 
 P. Value = 0.000 
 
 
 
 
 
Table 2: DM duration Vs eye complications 
Duration (in years) Eye complications Total 
Yes 
No.           % 
No 
No.           % 
< 1    14        (93%) 1           (7%) 15 
1-10   30        (79%) 8           (21%) 38 
> 10   14        (52%) 13          (48%) 27 
Total  58     22 80 
P. Value 0.000 
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Table 3: DM duration Vs renal complications 
Duration (in years) Renal complications Total 
Yes 
No.           % 
No 
No.           % 
< 1    15      (100%) 0         (0%) 15 
1-10   36       (95%) 2          (5%) 38 
> 10   25       (93%) 2          (7%) 27 
Total   76      4 80 
P. Value 0.091 
 
 
 
 
 
Table 4: DM duration Vs Cardiac complication 
Duration (in years) Cardiac complications Total 
Yes 
No.           % 
No 
No.           % 
< 1   13       (87%) 2       (13%) 15 
1-10   32      (84%) 6       (16%) 38 
> 10   19       (70%) 8        (30%) 27 
Total   64       16 80 
P. value 0.016 
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Table 5: DM duration Vs peripheral neuropathy 
Duration (in years) peripheral neuropathy Total 
Yes 
No.           % 
No 
No.           % 
< 1   14       (93%) 1         (7%) 15 
1-10   28        (74%) 10        (26%) 38 
> 10   13       (48%) 14         (52%) 27 
Total   55      25 80 
P. Value 0.000 
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Figure 10: Hypertension in the study population 
  
 
 
 
3.75%
26.25%
50%
20%
 
 
Underwieght (BMI.<19.9)
Healthy (BMI. 20-24.9)
Overwieght (BMI. 25-29.9)
Obese (BMI. 30-39.9)
 
 
Figure 11: BMI of the study population 
Mean 26.696 
SD 3.994  
SEM 0.44649 
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Figure 12: Fasting plasma glucose level  in the studied cases 
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Figure 13 Two Hours Post Prandial Blood Glucose level in the studied cases 
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Figure 14: Previous lipid profile testing in studied population 
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Figure 15: Cholesterol level in the studied cases 
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Figure 16: Triglyceride level in the studied cases 
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Figure 17:  HDL level in the studied cases 
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Figure 18: LDL level in the studied cases 
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Figure 19: CHD risk (LDL score) in the studied cases 
 
Mean 14.53 
SD 9.951  
SEM 1.244 
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Figure 20 CHD risk (Cholesterol score) in the studied cases 
 
Mean 13.06 
SD 9.057  
SEM 1.132 
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4. DISCUSSION 
 
During the period from July to December 2009 at the diabetes outpatient clinic, 80 
diabetic patients have participated in this study, questioned by detailed questionnaire 
and investigated. 
The background findings of the studied population are compatible with the literature 
from international population studies, as seen by the age, sex, type of DM, duration of 
DM, type of DM management and the family history of DM in the studied cases 
(figures 1,2,3,4,5,6).  
The relative decreased incidence of smoking (8.75%) and alcohol consumption (5%) in 
the studied cases may result from the fact that the majority of our cases (71%) were 
females; although 2 female patients were smokers, and usually these are considered as 
male habits. A second possibility is the increased medical and religious awareness of the 
patients about the hazards related to smoking and alcohol consumption. A third 
possibility is the relative advanced age of the studied cases (mean age 52.3 years) with 
the accompanying wisdom which encouraged a quite proportion of the patients who 
were Ex-smokers to quit smoking, same justification is applied to the much fewer ex-
alcoholic patients (figures 7,8). 
DM chronic complications: 
In relation to diabetes chronic complications the patients were asked for relevant 
complains and their files were reviewed for the clinical examination and investigations 
results. 
Eye complications 28% of the studied cases have them in the form of cataract and/or 
retinopathy. The study showed that eye complications are significantly more common in 
type 2 DM patients. (P value 0.000) (figure 9). Also, there is a statistically significant 
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relationship between prolonged DM duration and increased rate of retinopathy (P value 
0.000) as shown in (table 1). 
Interpretation: The proportion of patients with eye complications are expected to be 
higher due to the crude clinical assessment based mainly on the patients complains and 
the preliminary physical examination. Very few cases were referred to have proper 
ophthalmological assessment. Also, the literature states that diabetic retinopathy is more 
common in type 1(40%) than type 2(20%) and it is considered as the most common 
cause of legal blindness in individuals between the ages of 20 and 65 years. (50) This 
discrepancy can result from the relative small number of type 1 diabetes patients 
participating in the study (5 patients out of the 80 cases included in the study) and the 
crude clinical assessment of the patients causing any cataract to be diabetes related 
although it can result from other causes, including age related cataract. Our finding of 
prolonged DM duration increasing the rate of retinopathy is compatible with the 
literature stating that the duration of diabetes is the most important risk factor for the 
development and progression of diabetic retinopathy(49). 
 Renal complications (diabetic nephropathy): the patients were assessed for the presence 
of proteinuria and/or increased creatinine. They were present in only 6% of the patients. 
Diabetic nephropathy is more common in type 1 DM (P value 0.006) caused by the 
small number of type 1 DM patients participating in the study. See figure 9. Prolonged 
DM duration is associated with increased incidence of diabetic nephropathy. (P value 
0.091) (table 2). 
Interpretation: This underestimation of the renal complications may result from either of 
the following: 
• Testing for proteinuria by urine reagent test strips which have reduced sensitivity 
allowing detection of only gross proteinuria instead of microalbuminuria. 
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Microalbuminuria is the earliest detectable stage of diabetic nephropathy. 
Progression from microalbuminuria to clinical nephropathy can be delayed with 
intensive therapy to normalize blood glucose and blood pressure(29).  
• Some of the patients are hypertensive and treated by ACEI (Angiotensin Converting 
Enzyme Inhibitors) which protect and even reverse the early stages of diabetic 
nephropathy. 
• Patients undergoing dialysis for End Stage Renal Disease (ESRD) were excluded 
from the studied cases, due to its known association with dyslipidemia in the form 
of impaired HDL maturation and hypertriglyceridemia caused by the impaired 
clearance of triglyceride rich lipoprotein and their atherogenic remnants. The degree 
of dyslipdemia is affected by the dialysis modality; attenuated by hemodialysis and 
aggravated by peritoneal dialysis(50,51).  
The underestimation of diabetic nephropathy has lead to the insignificant association 
between prolonged DM duration and increased nephropathy incidence, especially the 
fact that with prolonged DM duration more patients are expected to develop ESRD and 
these are excluded from the study. 
Peripheral neuropathy : present in 29% of the studied cases. See (figure 9). Its 
prevalence increases significantly with prolonged disease duration (P value 0.000) as 
shown in (table 3). 
Cardiac complications: The patients were assessed for ischemic changes as indicated by 
history of clinically diagnosed cardiac event, ECG findings and echocardiography in the 
needed cases. Cardiac complications are present in 21.25% of the studied cases. They 
occur mainly in type 2 DM patients (P value 0.002).See (figure 9). Prolonged DM 
duration significantly increases the proportion of patients with cardiac complications ( P 
value 0.016) see (table 4). 
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Interpretation: The fact that diabetes mellitus is a major risk factor for CVD (2- to 4-
fold greater risk than that of individuals without diabetes) is well established. Both types 
1 and 2 diabetes confer a heightened risk for CVD. Type 2 diabetes is of particular 
concern because it is so common and usually occurs in persons of advancing age, when 
multiple other risk factors coexist (5,52). 
The study showed a statistically significant relation between prolonged diabetes 
duration and the increased rate of developing diabetes chronic complications (P value 
0.00) (table 5). 
A Sudanese study about the epidemiology of DM and IGT at Alkabashi area in 2005 
showed a high prevalence of 24.6% for DM, 7.3% for impaired fasting glucose and 
10.3% for impaired glucose tolerance. 68% of the known diabetic patients were 
uncontrolled with high prevalence of complications such as neuropathy (64.1%), 
retinopathy (15.4%) and nephropathy (14.3%)(53). 
Interpretation: the remarkable high prevalence of DM in this area exceeds the 
prevalences found in the other studied areas of Sudan and this may be explained by the 
homogeneous small community of Alkabashi being mostly of the same descent as 
compared with the heterogeneousity found in larger cities with definite role of genetical 
and environmental factors. The prevalence of diabetes complications tends to be higher 
in Alkabashi area (68%)when compared to our cases (53%) with the exception of 
retinopathy. This discrepancy can be attributed to the limited and primitive medical care 
expected in this remote area which denotes worse control and more complications. The 
decreased incidence of retinopathy may be explained by the need for sophisticated 
ophthalmological equipments to diagnose it which are expected to be unavailable at 
Alkabashi. 
Hypertension is present in almost 29% of the studied cases (figure 10). 
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Studying the body mass index (BMI) of the cases, it was found that 70% have increased 
BMI (overweight and obese) mostly belonging to type 2 diabetics as stated in the 
literature(23) .The mean BMI 27 kg/m2(overweight). See figure 11.The mean BMI in 
type 1 DM is 25 kg/m2 (healthy) and in type 2 DM patients is 27 kg/m2 (overweight). 
 The majority of the studied cases (> 60%) have poorly controlled DM, as shown by the 
increased FPG and 2 hours post-prandial glucose levels (figure 12,13). 
Interpretation: the poor glycemic control may result from any of the following:  
• The increased BMI of the studied cases (although losing excess weight is one of the 
mainstays in the management of diabetics).  
• The patients compliance with the medications, dietary and life style improvement 
must be checked and if these are inadequate the diabetic educator should motivate 
them about the benefits of good glycemic control in decreasing the complications.  
• The availability of the drugs and glucometers for monitoring should be checked. 
Lipid profile : 
Previous lipid profile testing:  the test was previously requested from only 27.5% of the 
studied cases, see figure 14, despite the well known association between DM and 
dyslipidemia and the resulting cardiovascular disease being the primary cause of death 
among diabetic patients of both type 1 and 2(5,33).  
Interpretation: The decreased request of lipid testing in diabetes may result from the 
economical status of the patients making the clinician reducing the requested 
investigations to reduce the cost of the medical services for the patients allowing them 
to focus on provision of the relatively expensive treatment. Another possibility is that 
the decreased awareness of the medical practitioners;  who used to treat the patients 
before joining the diabetes outpatient clinic at SUH, about the significance of 
dyslipidemia in diabetes and its relation with cardiovascular disease. 
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Lipid profile in the studied cases:  
Hypercholesterolemia is present in 31% of the cases, mean cholesterol  189.8  mg/dl 
(desirable according to the NCEP) 
Hypertriglyceridemia is found in 36.25% of the cases, mean TG 142.5  mg/dl (normal 
according to the NCEP) 
Decreased HDL to a level causing increased CHD risk is found in 95% of the cases, 
mean HDL    41.1 mg/dl(moderate risk according to the NCEP) 
Increased LDL with resultant increase in CHD risk is found in 76% of the cases, mean 
LDL     134.4 mg/dl(borderline high risk according to the NCEP) 
In type 1 DM patients the mean values for the lipid profile are: borderline high 
cholesterol, normal TG, moderate risk HDL and borderline high LDL 
In type 2 DM patients the mean values for the lipid profile are: desirable cholesterol, 
normal TG, moderate risk HDL and borderline high LDL) 
The lipid profile of type 1 DM patients is worse than that of type 2 patients in respect to 
the degree of dyslipidemia and the number of patients having hypercholesterolemia, 
hypertriglyceridemia, decreased HDL and increased LDL.  
Interpretation: this matches with the literature(37,21) but is statistically insignificant and 
can be attributed to the small number of type 1 DM patients participating in this study. 
The study showed a statistically significant relation between prolonged diabetes 
duration and increasing triglyceride, increasing total cholesterol, increasing LDL and 
decreasing HDL levels.  
• A cross-sectional study was undertaken to determine the serum lipid profile of 
diabetes mellitus (DM) patients receiving treatment at Gaborone City Council 
clinics, Gaborone, Botswana. A total of 401 patients were studied over a 3-month 
period(54).  
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It was found that 33.5% had hypercholesterolaemia and 38.9% hypertriglyceridaemia. 
The mean low-density lipoprotein (LDL) levels were higher in females than in males, 
but there was no difference inLDL levels between type 1 and 2 DM patients. There was 
no difference in cholesterol, triglyceride and high density lipoprotein (HDL) levels 
between genders or between type 1 and 2 patients.  
Of the subjects 61.2% had hypertension, 27.2% were overweight, 56.4% were obese, 
4% had a history of smoking and 3.1% had a history of alcohol intake. 
Hyperlipidaemia was associated with high body mass index. Only hypertrigl-
yceridaemia was associated with high blood pressure. 
Hyperlipidaemia was not associated with exercise, smoking or alcohol consumption in 
the DM patients studied(54). 
• In a study of DM patients in Ethiopia 18.5% were found to have 
hypercholesterolaemia and 14.2%  hypertriglyceridaemia respectively. In the same 
study hypercholesterolaemia was found in a high proportion of females and type 2 
DM patients (55). 
• In a cross-sectional survey in South Africa undertaken to assess dietary patterns in 
type 2 DM patients (133 men, 155 women), high triglyceride levels were detected in 
24 - 25% of men and in 17 - 18% of women (56). 
Our findings are comparable to Botswana, South Africa and to a lesser extent to 
Ethiopia. This can be justified by the similarities geographically, environmentally 
(dietary patterns) and ethnically.  
• A study from USA showed that 18.0% of participants had poor glycemic control 
(hemoglobin A1c level > 9.5%) as compared to 40% in our study, and 65.7% had 
blood pressure less than 140/90 mm Hg which is comparable to our percentage 
of 71%. Cholesterol was monitored biannually in 85.3% of participants, but only 
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42.0% had LDL cholesterol levels less than 3.4 mmol/L (<130 mg/dL) which 
was 52.5% in our cases(57). 
So we have almost comparable percentages of hypertension and LDL cholesterol with 
the USA population, but our glycemic control is twice as bad as theirs due to the poor 
diabetes management policies and programs in our countries compared with the USA 
enormous funds and the well established infrastructure for the proper multidisciplinary 
management of diabetes. It is worth mentioning that the USA study has used HbA1C as 
an indicator of the long term glycemic control which is better than our indicators being 
FPG and 2 hours postprandial blood glucose which only indicate the short term 
glycemic control.  
CHD risk estimation (using the Framingham heart study prediction score): 
The mean of the estimated CHD risk over the next 10 years was found to be 14%.  
Interpretation: It is increased when compared with low risk group which was calculated 
for a person the same age, sex, optimal blood pressure, LDL-C 100-129mg/dl or 
cholesterol 160-199 mg/dl, HDL-C 45 mg/dl for men or 55 mg/dl for women, non-
smoker and no diabetes. This high risk can be predicted from the coexisting 
hypertension in 25% of the studied cases, the increased BMI and the dyslipidemia found 
in them. The Framingham Heart Study(40) has limitations which make its application in 
our cases not very accurate and reliable but since it fits our research financial and 
clinical set up its use can definitely give us a good clue about CHD risk in our patients.  
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5.1 CONCLUSION 
 
• According to my knowledge, it is the first time for such a study in Sudan estimating 
the CHD risk in diabetes patients using the Framingham scoring system. 
• DM related chronic complications are found in almost 53% of our cases and they 
increase significantly with prolonged disease duration. 
• Social habits contributing to CHD risk are assessed and almost 9% of the studied 
cases are found to be smokers and 5% are alcohol consumers. 
• Hypertension with its known association with DM and contribution to CHD is 
found in 29% of our cases. 
• Overweight and obesity are present in 70% of the studied cases with mean BMI 
about 27 (overweight), which markedly contributes to the poorer DM control and 
the higher CHD risk.  
• The short-term glycemic control is poor in 65% of our cases. 
• The study showed decreased awareness among the medical staff who used to take 
direct care of diabetes patients before joining the diabetes clinic in SUH about the 
importance of dyslipidemia in diabetics as reflected by the lipid profile test being  
requested from only 28% of the cases. 
• The lipid profile of the studied cases show hypertriglyceridemia in 36.25%, 
hypercholesterolemia in 31%, decreased HDL-cholesterol to the level conferring 
increased risk of CHD in 95% and increased LDL-cholesterol in 77%. 
• The lipid profile in type 1 DM patents is worse than type 2 
• The lipid profile worsens significantly further with prolonged disease duration. 
• The mean CHD risk is estimated to be 14% in the following 10 years for the studied 
cases. This high risk needs great attention by both the patients and their treating 
physicians and aggressive intervention to control the factors increasing the risk; like 
hypertension, smoking and most importantly the dyslipidemias. 
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RECOMMENDATIONS 
 
• Further studies spanning greater duration and involving larger numbers of diabetes 
patients (especially type 1) should be carried out to assess the patterns of 
dyslipidemia and the resultant CHD risk in adult Sudanese DM patients. The results 
of these studies should be utilized to improve patients management and hence 
decreasing the morbidity and mortality of this grave disease. 
• Medical conferences and meetings should be held regularly updating the medical 
team taking care of DM patients about the significance of dyslipidemia in DM and 
the approach of its management. 
• Earlier detection of dyslipidemia is very useful in preventing the complications so 
earlier requesting of lipid profile test is recommended. 
• Establishment of the multidisciplinary team approach in DM management with 
inclusion of dentists, ophthalmologists, foot care providers and psychologist beside 
the already recruited physicians, diabetic educators, nutritionists and pharmacists. 
• Due to the known limitations of the Framingham scoring system, better CHD risk 
assessment scoring systems which fits more to our population should be applied. 
• We could not measure HbA1C for our cases due to financial limitation. But, 
implementation of HbA1C measurement in the routine follow up of DM patients as 
a tool for estimation of the long-term diabetes control is highly recommended. 
Luckily, HbA1C measurement is already practiced biannualy for the diabetics 
joining the clinic of SUH for the last 2 years. 
• Implementation of the ABC approach in patient management by controlling A: 
HbA1C which indicates the glycemic control, B: Blood pressure control and C: 
  66
Cholesterol and other parameters of lipid profile control collectively this will result 
in marked reduction in DM morbidity and mortality. 
• Beside taking the medications, the patients should be encouraged to stop smoking, 
lose excess weight, eat healthy diets and exercise. This will greatly benefit their DM 
control and overall health. 
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Appendix 1 
Questionnaire 
University of Khartoum 
Graduate college 
MEDICAL & HEALTH STUDIES BOARD 
Date:    /    / 2009                                                        serial number: (        )                                      
Name: …………………………………………………………………     
Age: ………                              Sex:     Male             Female                            
Telephone……………… 
Residence: …………………………         Occupation: ……………………… 
Type of diabetes: …………………  Duration: …………………………. 
Types of diabetes management:  
Diet only  Tabs  Insulin  Insulin +Tabs  
Family history of diabetes: Yes           No     
Smoking:  Yes       No                           Alcohol: Yes        No  
Clinical complications:  
Eye  Renal  Cardiac      Peripheral neuropathy   
Hypertensive: Yes        No                    Blood pressure: ………… 
Antihypertensive drugs: ………………………………………………………      
Ht.: …….  Wt.: ………  BMI.: ……… 
Previous lipid profile testing       Yes                  No  
Investigations:                                                   
FBG:……………………                                         2 hr PP………….        
Triglyceride ……………                                         Cholesterol …………… 
HDL cholesterol……….                                         LDL cholesterol………. 
calculated CHD risk:……. 
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Appendix 2 
Reagents Manual 
 
 
